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Sumário  
Revisão da literatura: A grelina é um peptideo acilado com 28 
aminoácidos isolado pela primeira vez a partir da mucosa gástrica do 
rato, sendo o seu principal local de produção as células X/A deste tecido. 
Sistemicamente, a grelina afeta vários sistemas como o endócrino, 
gastrointestinal, o cardiovascular, o pulmonar, o reprodutor, o sistema 
nervoso central entre outros1, 2.  
A grelina é o ligando endógeno do recetor dos secretagogos da hormona 
do crescimento (GHSR-1a) e promove a libertação desta hormona por 
parte da hipófise de forma independente do tradicional recetor da 
hormona libertadora de hormona do crescimento1. Para além da forma 
acilada da grelina, existe também uma forma desacilada denominada 
des-acil grelina. Esta variante apresenta uma constituição aminoacídica 
igual à grelina, mas não tem o grupo acil acoplado à serina 3, estando 
por isso impedida de se ligar ao GHSR-1a3. Face à comprovada existência 
de efeito fisiológicos atribuíveis à des-acil grelina, que em várias 
situações são partilhados com a grelina, foi sugerida a existência de 
outro recetor para além do tradicional GHSR-1a4. 
Recentemente, foram atribuídas acções importantes à grelina no globo 
ocular, quer no segmento anterior como no segmento posterior. No 
segmento anterior o seu ARNm foi identificado, encontrando-se este 
principalmente na face posterior da íris e no epitélio ciliar não 
pigmentado. Foi demonstrado que a grelina relaxa os músculos 
constritor e dilatador da pupila5. A presença de grelina foi ainda 
detetada no humor aquoso, estando os seus níveis diminuídos em 
doentes com diferentes tipos de glaucoma
6, 7
. No segmento posterior, a 
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grelina foi identificada na retina e implicada na fisiopatologia da 
retinopatia da prematuridade8.  
Objetivo: Considerando assim que este peptídeo parece desempenhar 
um papel tanto na fisiologia como na fisiopatologia ocular, o objetivo 
deste trabalho é investigar a presença de grelina e do seu recetor neste 
órgão e avaliar o efeito deste sistema na modulação da pressão 
intraocular.  
Métodos: A deteção de grelina e do seu recetor no globo ocular de rato 
foi efetuada através de immunofluorescência. Adicionalmente avaliou-se 
a sua distribuição relativamente aos componentes musculares 
intraoculares e às células endoteliais vasculares. Com vista ao estudo da 
modulação da pressão intraocular, a sua medição foi realizada com um 
tonómetro de impacto comercial usado em veterinária. Visto este 
dispositivo estar calibrado apenas para o cão, o gato e o cavalo, 
procedeu-se à sua calibração para os modelos animais utilizados neste 
protocolo, com vista à obtenção de medições mais fidedignas. Esta 
calibração foi feita comparando as medidas do tonómetro com 
manometria intraocular in vivo. Em ambas as espécies o tonómetro 
apresentou uma boa correlação com a manometria. A indução de 
hipertensão ocular foi realizada em dois modelos animais (coelho e rato) 
através da adaptação de um modelo previamente descrito no coelho9. 
Com as alterações introduzidas verificou-se um aumento da pressão 
intraocular semelhante à previamente descrita, mas neste caso com uma 
maior estabilidade e durante um período de tempo mais longo. 
Posteriormente procedeu-se à implementação deste modelo no rato, 
tendo sido demostrada a aplicabilidade da técnica, com visível 
desenvolvimento de hipertensão ocular. Uma vez validado o modelo, 
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procedeu-se ao estudo dos efeitos da grelina e da des-acil grelina na 
modulação da pressão intraocular através da administração 
subconjuntival de um dos peptídeos. Com vista à avaliação das vias sub-
celulares envolvidas neste processo, foi realizado o bloqueio seletivo da 
via da ciclooxigenase ou da via da sintase do óxido nítrico.  
Resultados/Discussão: Os resultados destes estudos revelam que a 
grelina é produzida pelo globo ocular, nomeadamente pelos processos 
ciliares e pela retina. O recetor da grelina também está presente no 
globo ocular, tendo sido a sua expressão detetada na rede trabecular, 
estroma dos processos ciliares, epitélio corneano, íris e em toda a 
coróide. Nos modelos animais de hipertensão ocular, tanto a grelina 
como a des-acil grelina demonstraram ter um efeito hipotensor, sendo 
que a des-acil grelina apenas o conseguiu no rato. Estes estudos 
acrescentam novos argumentos a favor de um papel do sistema grelina-
GHSR na fisiologia ocular. A produção de grelina pelos processos ciliares 
aliada à presença do seu recetor no tecido ocular, nomeadamente em 
componentes responsáveis pela dinâmica do humor aquoso, fortalece a 
hipótese do envolvimento deste peptídeo na fisiopatologia do glaucoma. 
Fazendo a ponte para uma potencial aplicação clínica, podemos 
considerar que o efeito hipotensor demonstrado por este peptídeo 
poderá ser utilizado como futuro alvo terapêutico nas situações de 
glaucoma, uma das principais causas de cegueira no mundo ocidental. 
 
 
 
Palavras-chave: Grelina, des-acil grelina, GHSR, glaucoma, pressão 
intraocular,  imunofluorescência.   
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Abstract 
Background: Ghrelin is a 28 amino acid acylated peptide first isolated 
from the rat’s stomach and is mainly produced by the X/A cells of the 
gastric mucosa. Ghrelin exerts its action on several organ systems, 
namely the endocrine, the gastrointestinal, the cardiovascular, the 
pulmonary, the reproductive and the central nervous system, among 
others1, 2.  
Ghrelin is the endogenous ligand for the growth hormone secretagogues 
receptor (GHSR-1a), promoting growth hormone release of growth 
hormone from the pituitary independently from the growth hormone 
release hormone receptor1. Another variant of ghrelin is its unacylated 
form des-acyl ghrelin. This variant is identical to ghrelin, except for the 
acyl group in the serine 3, thus being unable to bind GHSR-1a3. Since 
some effects have been attributed to both ghrelin and des-acyl ghrelin, 
the existence of a different receptor responsible for ghrelin’s actions 
besides GHSR-1a has been proposed4. 
In recent studies, ghrelin has been proposed to play important roles in 
the ocular tissue, both in the anterior and posterior segments.  
Regarding the anterior segment, ghrelin’s mRNA was identified in the 
posterior surface of the iris and in the non-pigmented ciliary epithelium. 
This peptide was also shown to induce the relaxation of the iris sphincter 
and dilator muscles5. Ghrelin has also been implicated in glaucoma, 
being its levels decreased in the aqueous humour of patients suffering 
from different types of this pathology6, 7. Regarding the posterior 
segment, ghrelin has been identified in the retina and implicated in the 
pathophysiology of retinopathy of prematurity
8
.  
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Aims: Bringing together ghrelin’s involvement in the ocular physiology 
and in the pathophysiology of glaucoma, the aim of this work is to 
investigate the presence of ghrelin and its receptor in the ocular tissue 
and to evaluate the effect of the ghrelin-GHSR-1a system in the IOP 
modulation. 
Methods: The detection of ghrelin and GHSR-1 expression in the ocular 
tissue was performed through the immunofluorescence technique. The 
position of these distribution patterns relatively to the localization of the 
ocular contractile elements and vascular endothelial cells was also 
assessed.  In order to study the modulation of intra-ocular pressure, its 
measurement was performed using commercial available rebound 
tonometer. The tonometer was calibrated for both experimental models 
as it does not possess calibration for the animals used in our protocols. 
The tonometer correlated very well with in vivo manometry and in the 
experimental protocols it proved to be very efficient, allowing an easy, 
fast and user-independent measurement of the IOP. Ocular hypertension 
was induced in two different animal models (rabbit and rat) through the 
adaptation of an experimental model previously described in the rabbit. 
The alterations introduced to the protocol proved to induce a similar 
increase in the IOP, but in a more sustained and stable fashion and 
during a longer time period. After the model validation in the rabbit, 
intraocular hypertension was also successfully induced in the rat through 
the same experimental protocol, highlighting its technical applicability. 
Once the model was optimized, ghrelin and des-acyl ghrelin’s effect in 
the modulation of the intraocular tension was evaluated through 
subconjunctival administration of either of the peptides. In order to 
assess the sub-cellular pathways involved in this process, either the 
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cyclooxygenase or the nitric oxide synthase pathway was selectively 
blocked. 
Results/Discussion: The results of the above presented studies reveal 
that ghrelin is produced by the ocular tissue, namely by the ciliary 
processes and the retina. Ghrelin receptor is also expressed in the eye, 
more precisely in the trabecular meshwork, ciliary proceses stroma, 
corneal epithelium, iris and throughout the choroid. In the ocular 
hypertension models both ghrelin and des-acyl ghrelin were able to 
significantly decrease the intraocular pressure, being that des-acyl 
ghrelin was only able to do so in the rat. These data increase the already 
existing evidence for a role for the ghrelin-GHSR system in the ocular 
physiology. The endogenous production of ghrelin by the ciliary body 
together with the presence of the ghrelin receptor in the ocular tissue, 
namely in the components responsible for aqueous humour dynamics, 
strengthens previous data that associated ghrelin with the 
pathophysiology of glaucoma. Translating these findings into a potential 
clinical application, the IOP-lowering effect of ghrelin points to a possible 
therapeutic role in glaucoma, one of the main causes of blindness in 
western world. 
 
 
 
 
Keywords: Ghrelin, des-acyl ghrelin, GHSR, glaucoma, intraocular 
pressure, immunofluorescence. 
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1. Ghrelin and related peptides   
Ghrelin is a 28 amino acid peptide that presents a fatty acid at serine 3 
and was first isolated from the rat’s gastric mucosa. It is the endogenous 
ligand of the somatosecretagogue’s receptor type 1a (GHSR-1a), 
promoting growth hormone’s release from the pituitary1.  
Ghrelin’s precursor is encoded by a gene composed by 5 exons and 4 
introns  located on chromosome 3 (3p25-26)10. There have been 
described several transcriptional variants associated with the ghrelin 
gene: the first variant encodes a 117 amino acid preprohormone with 
82% homology between species named preproghrelin1; the second 
variant is 5’ truncated at exon 2 and encodes prepro des-Gln14-ghrelin11, 
12; the last variant has exon 3 deleted and encodes exon 3 deleted-
preproghrelin 13, 14.  
After preproghrelin has been synthetized, the 23 amino acid signal 
peptide is cleaved resulting in a 94 amino acid peptide named 
proghrelin. This prohormone undergoes a post-translational modification 
in which an acyl group is added to the Ser 31, 15. This modification is 
carried out by ghrelin octanoyl-acyltransferase (GOAT), an enzyme 
belonging to a family of membrane bound O-acyltransferases (MBOAT) 
16, 17.  The localization of GOAT overlaps the localization of ghrelin17, 18 
and among all the enzymes of the family only GOAT is able to add the 
acyl group to ghrelin. This modification, along with the first five amino 
acids, is necessary for ghrelin’s linkage to GHSR-1a19.  
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After acylation, proghrelin is cleaved into the 28 amino acid acylated 
ghrelin and a 66 amino acid propeptide named C-ghrelin12. This process 
is mediated by prohormone convertase 1/3 (PI3K)15.  
Posteriorly C-ghrelin can either be processed into smaller peptides, 
namely a 23 amino acid peptide designated obestatin20, or circulate as a 
full peptide21. Although ghrelin and C-ghrelin derive from the same 
prohormone, there does not appear to be a direct relation between 
ghrelin and C-ghrelin levels, neither in human serum21 nor rat plasma 
and tissues22, suggesting that C-ghrelin may be an independently 
regulated gene-derived hormone with distinct functions. Obestatin also 
derives from proghrelin and was initially discovered through 
bioinformatics techniques. It has posteriorly been isolated from the rat’s 
stomach and was first described as a hormone possessing contrary 
effects to ghrelin, namely in reducing food intake, bodyweight gain and 
gastric emptying in rats20. Furthermore, it has attributed a role in the 
activation of GPR39, a GPCR related to the ghrelin receptor family. This 
activation was subsequently questioned by other studies and there is still 
some controversy regarding obestatin’s actions and its receptor23, 24. 
As said above, the second splice variant originates preprodes-Gln14-
ghrelin. This preprohormone is processed similarly to preproghrelin, but 
originates a variant of ghrelin devoid of glutamine at position 14 named 
des-Gln14-ghrelin11. Interestingly, although the levels of this peptide are 
negligible in humans, des-Gln14-ghrelin maintains the ability to stimulate 
GHSR-1a with the same potency of ghrelin11, 12.  
The last splice variant encodes exon 3-deleted preproghrelin. This 
preprohormone is also able to originate functional acylated ghrelin but 
Ghrelin-GHSR system in the eye: local regulation and 
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completely lacks the sequence coding for obestatin, generating a 
truncated C-ghrelin peptide with a novel 16 amino acid C-terminal 
peptide (∆3D)13.  
 
Fig.1 Overview of the ghrelin gene and derived peptides. Exons are illustrated as colored boxes with 
corresponding numbers. Blue box) ghrelin’s gene can originate different mRNA transcripts through 
alternative splicing. Left part of red box) Preproghrelin is encoded by exons 1-4. Exon 1 and part of exon 
2 encode ghrelin whereas the remainder of exon 2 and exons 3 and 4 encode C-ghrelin. Left part of 
purple and light blue boxes) Proghrelin is acylated and then cleaved by PI3K originating ghrelin and C-
ghrelin. White box) Ghrelin can be posteriorly deacylated and originate des-acyl ghrelin. Right part of 
white box) Exon 3 deleted transcript is unable to originate obestatin but is capable of originating ghrelin 
or des-acyl ghrelin. 
 
Once acylated ghrelin is produced, it can be further processed and 
originate  des-acyl ghrelin, a peptide structurally equal to ghrelin except 
for the octanoil group at serine 3. 3, 19, 25.  Although some studies have 
tried to identify the enzymes responsible for the deacylation of ghrelin26-
28, no conclusion has been drawn yet (Figure.1). Once released into the 
bloodstream, acylated ghrelin circulates associated with triglyceride rich 
lipoproteins (TRL), high density lipoproteins (HDL), very high density 
lipoproteins (VHDL) and, to some extent, with low density lipoproteins 
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(LDL), while des-acyl-ghrelin circulates as a free peptide in plasma.25,27, 29 
Des-acyl ghrelin levels represent about 90% of the total circulating 
ghrelin11, 19, 25, being the plasma concentration of acylated ghrelin 10-20 
fmol/mL and the total concentration 100-150 fmol/mL (including 
acylated and non-acylated forms) 30,31.  
Regarding ghrelin production, two thirds of the total ghrelin are 
produced by the X/A cells of the gastric oxyntic mucosa32. The remaining 
one third is produced by the intestine, pancreas, kidney, placenta, 
endometrium, lymphatics, gonads, adrenal glands, thyroid gland, heart, 
lung, pituitary gland, hypothalamus, B and T cells, neutrophils and the 
eye1,33,34,5, 32. 
 
2. Growth hormone secretagogue receptor (GHSR)  
GHSR-1a was first discovered in the pituitary and in the hypothalamus 
previously to the identification of its endogenous ligand ghrelin35. The 
stimulation of this receptor by ghrelin promotes the release of GH 
independently from the stimulation of GHRHR1, 30, 35, 36. GHSR-1a is a 
typical GPCR, presenting seven transmembrane domains, and belongs to 
a small sub-family of GPCRs that also includes the motilin receptor, the 
neurotensin receptors, the neuromedin U receptors and GPR39
30, 35, 37
.  
The human gene encoding GHSR is located on chromosome 3q26.2. 
There are currently two identified splice variants of the GHSR gene. One 
variant encodes the full length isoform of the receptor, GHSR-1a, which 
contains 366 amino acids and the seven transmembrane domains. The 
second variant encodes a C-terminal truncated isoform composed of 
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only 289 amino acids and five transmembrane domains35, 38 (Figure.2). 
Although the two isoforms have been described, GHSR-1b is unable to 
bind ghrelin or other known growth hormone secretagogues35. However, 
this truncated isoform has been identified in numerous organs such as 
the heart, thyroid, pancreas, spleen and adrenal glands33,2 and has been 
proposed to interact with GHSR-1a and to modulate its activity39,40. 
Regarding GHSR-1a, it is also widely expressed in tissues such as the 
stomach, intestine, pancreas, spleen, thyroid, gonads, adrenal glands, 
kidney, heart, lung, liver, adipose tissue and bone4, 30, 33, 41-43. 
 
 
Fig. 2 Overview of the GHSR gene and derived receptor isoforms. Exons are illustrated as colored boxes 
with corresponding numbers. Red rectangle represents part of the intron between exons 1 and 2. Blue 
box) GHSR gene can originate two splice variants. One variant contains the two exons and originates the 
full-length receptor. The second contains only exon 1 and part of the intron and originates a truncated 
form of the receptor. Left part of red box) This variant encodes the full-length GHSR-1a receptor. Exon 1 
encodes domains I-V and exon 2 encodes domains VI-VII. Right part of red box) This variant has a stop 
codon in the intron and generates a truncated version of the receptor with only 5 domains encoded by 
exon 1. 
 
GHSR-1a is constitutively active44 and presents two binding sites: one 
that is located in the transmembrane domain number 3 and binds 
ghrelin, as well as other peptide and non-peptide synthetic agonists19, 45; 
and a second one that was proposed to bind adenosine
46
. In the 
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somatotropes, the activation of the GHSR-1a stimulates the enzyme 
phospholipase C (PLC), which promotes the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) 
and IP3. IP3 subsequently binds its receptor on the sarcoplasmic 
reticulum, promoting a transient increase in the intracellular calcium 
concentration. DAG activates the PKC and promotes the inhibition of 
potassium channels, leading to the membrane depolarization and 
posterior opening of voltage dependent calcium channels. This process 
generates a persistent elevation of intracellular calcium levels47. 
Nevertheless, this is not the only subcellular pathway activated by 
ghrelin. This hormone is able to promote cellular proliferation through 
GHSR-1a activation of subcellular signaling pathways such as the 5’ 
adenosine-monophosphate activated protein kinase pathway48, the 
MAPKs pathway, in particular MAPK p44/p42, (also known as the 
extracellular signal regulated protein kinase ERK 1/2)49-51, the 
transcriptional factor Elk 150, the Akt/PI3K pathway49 and tyrosine 
kinases pathways
51
. Moreover, it appears to inhibit several inflammatory 
and pro-apoptotic pathways52. Ghrelin also stimulates the activation of 
the NO/cGMP pathway53, 54, as well as the increase of the PPARγ2 in 
differentiated adipocytes, promoting adipogenesis through a GHSR-1a 
dependent pathway55 (Figure 3). 
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Fig. 3 Intracellular pathways involved in ghrelin’s effects. Top left). Ghrelin binds to the GHSR-1a, a Gq 
protein coupled receptor, leading to the activation of PLC. This enzyme converts PIP2 into IP3 and DAG. 
IP3 promotes Ca2
+
 release from the sarcoplasmatic reticulum; DAG inhibits K
+
 channels, inducing the 
opening of voltage-dependent L-type Ca2
+
 channels in the cellular membrane. The increase of 
intracellular Ca2
+
 results in membrane depolarization. Top right). Ghrelin activates a tyrosine kinase 
receptor leading to the activation of the Ras protein. The double phosphorylation of the Ras protein 
results in the MAPK, which needs another phosphorylation to enter the nucleus and regulate cell 
proliferation. Ghrelin also binds to an unknown receptor which activates ERK1 and ERK2 and Akt/PI3K, 
resulting in an anti-apoptotic effect. Bottom left). In endothelial cells ghrelin stimulates a G-protein-
coupled system which activates GC. This enzyme transforms GTP into cGMP, which leads to the 
activation of NOS, increasing NO levels. NO then promotes relaxation of the smooth muscle cell by 
entering it. Bottom right). In adipocytes ghrelin binds GHSR-1a and stimulates the PPARγ, a transcription 
factor that regulates genetic transcription and promotes adipogenesis. From Ghrelin: production, action 
mechanisms & physiological effects
56
. 
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3. Ghrelin’s actions  
3.1 Acylated ghrelin 
Ghrelin is responsible for multiple actions in numerous organs and 
tissues. As the endogenous ligand for GHSR-1a, ghrelin promotes GH 
release from the pituitary through the stimulation of this receptor1, 47, 57, 
58. In addition, ghrelin is able to stimulate the release of GH dependently 
on GHRHR59, 60.  It is also able to enhance the secretion of corticotropin-
releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and 
prolactin and to inhibit the release of GnRH and gonadotropins2, 61-66.   
Another well documented effect of ghrelin is the regulation of 
hunger/satiety cycle. Ghrelin has an orexigenic effect and its levels 
increase before meals and decrease post-prandially67-70. Furthermore, 
ghrelin seems to play an important role in body weight regulation, as its 
levels increase in response to weight loss and low-calorie diets67 and 
decrease in response to weight gain, forced overfeeding71 or high-fat 
diets
72
.  
Ghrelin presents significant effects in the metabolism of glucose and 
lipids. It increases plasma glucose levels due to direct effect on 
hepatocytes, where it modulates glycogen synthesis and 
gluconeogenesis, but also through inhibition of insulin secretion
73-75
. This 
effect is regulated by of a negative feedback loop, since insulin and 
glucose decrease ghrelin levels76, 77. Regarding the adipose tissue, ghrelin 
is responsible for preadipocytes proliferation and for an increase in 
insulin-induced glucose uptake in developed adypocites, which is 
Ghrelin-GHSR system in the eye: local regulation and 
pathophysiological implications 
Chapter I - Introduction 
11 
 
 
 
associated with a promotion of lipogenesis78-80. It has also been shown to 
inhibit lipolysis in vitro81. 
In the central nervous system (CNS) ghrelin interferes in the 
enhancement of memory and learning82-85, modulation of sleep86-91 and 
control of the response to stress82, 92. 
In the gastrointestinal system, it is able to stimulate gastric emptying and 
promote jejunal motility. Ghrelin also exerts a protective effect in the 
gastric mucosa and is involved in the regulation of acid secretion93-97. 
The human lung has been indicated as one of the organs that produce 
ghrelin42, 98. In an experimental model of pulmonary hypertension, 
administration of exogenous ghrelin attenuates pulmonary vasculature 
remodeling and right ventricle hypertrophy99. 
Concerning the muscular tissue, all three, skeletal, smooth and cardiac 
muscles were described to be affected by ghrelin. In the skeletal muscle, 
ghrelin increases the permeability to chloride, which leads to a decrease 
in membrane’s resting potential100. In endothelin-1 (ET-1) precontracted 
internal mammary arteries101 ghrelin induces vascular smooth muscle 
relaxation, being this hypotensive effect dependent on calcium activated 
potassium channels and associated with a decrease in the nitric oxide’s 
bioavailability102. 
In the heart, this hormone has negative inotropic and lusitropic 
effects103,104. The negative inotropic effect occurs as a response to 
ghrelin, des-Gln14-ghrelin and des-acyl ghrelin103. Ghrelin’s effect is 
dependent on calcium activated potassium channels and independent 
from GHSR-1a103, 104. These potassium channels also participate in the 
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negative lusitropic effect 104. This hormone also decreases the afterload 
and increases cardiac output without altering the heart rate105; increases 
coronary perfusion pressure and the blood flow on its 
microvasculature106 and inhibits the cytokines produced after an 
increase in NO bioavailability, ameliorating endothelial function107. 
Recently it was reported by Zhang et al. that ghrelin might protect the 
heart from disease induced by oxidative stress, since it prevented H9c2 
cardiac myocytes apoptosis52.  
In male reproductive system, ghrelin is present in Leydig cells since birth 
and it plays a role in their survival108, 109. However, the main effect of 
ghrelin in this system is the suppression of the reproductive axis during 
periods of hunger and negative energetic metabolism
110
. In the female 
reproductive system, ghrelin is expressed at the ovary in all phases of the 
reproductive cycle and seems to play a role in embryogenesis33, 111. 
The immune system is also affected by ghrelin’s actions. Chronic 
administration of exogenous ghrelin preserves thymus architecture and 
influences T lymphocytes production112. In addition, ghrelin is expressed 
in T lymphocytes and upon their activation both ghrelin and des-acyl 
ghrelin are released by these cells34.  Regarding pro-inflammatory 
cytokines, ghrelin has been shown to inhibit the synthesis of IL-1β, IL-6 
and TNF-α suggesting an anti-inflammatory role for this peptide
34, 107, 113
.    
Finally, ghrelin interferes in bone physiology, promoting both the 
formation and differentiation of osteoblast and osteoblast cell lines as 
well as an increase in bone mineral density114-117 (Figure 4).  
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Fig.4 Summary of ghrelin’s action. Adapted from: Rocha-Sousa, A., et al. 2010
118
. 
 
3.2. Des-acyl ghrelin’s actions  
As previously mentioned, des-acyl ghrelin is a non-acylated form of 
ghrelin that is unable to bind GHSR-1a. Although it was initially 
considered to be biologically inactive, it has currently been attributed 
diverse effects in numerous organ systems.  Depending on the 
experimental conditions, some of these effects are similar, contrary or 
independent when compared to ghrelin’s effect.  
In the cardiovascular system, des-acyl ghrelin has a negative inotropic 
effect that is even more pronounced than that exhibited by ghrelin. This 
effect is modulated by cyclooxygenase (COX), due to the production of  
prostacyclin (PGI2), and dependent on the endocardial endothelium
103. In 
H9c2 cardiomyocytes, which do not express GHSR-1a, both ghrelin and 
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des-acyl ghrelin bind with the same affinity to a common site and inhibit 
apoptosis through the same pathway (Figure.3 top right)119. In HIT-T15 
pancreatic β-cells120 and  human osteoblast cells, both peptides are able 
to promote cellular proliferation121. Contrary to ghrelin, des-acyl ghrelin 
is able to inhibit gastric emptying as well as food intake122, 123. In primary 
hepatocytes, des-acyl ghrelin inhibits glucose output and opposes 
ghrelin’s effect on glucose release124. 
All the previous data suggest the existence of alternative receptors 
responsible for such actions. It is possible that there is a common 
receptor responsible for ghrelin and des-acyl ghrelin’s analogous actions, 
as well as an independent receptor for des-acyl ghrelin. However, to 
date this question remains to be clarified. 
 
 
4. General anatomy of the eye 
The eye is divided in 3 compartments: the anterior chamber, the 
posterior chamber and the vitreous cavity. Both anterior and posterior 
chambers are filled with aqueous humour (AqH) while the vitreous cavity 
is filled with vitreous humour. Regarding its constitution, the ocular 
globe is composed by 3 concentric layers. The outermost is the structural 
layer and is composed by the cornea anteriorly and sclera posteriorly. 
The middle layer is the vascular layer of the eye, also known as uvea. 
Finally the innermost layer is the neurosensory layer and is composed by 
the retina. 
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4.1 Cornea and sclera 
The cornea is a completely transparent structure that occupies the 
center of the anterior pole of the eye and contributes to the focusing 
power of the eye. In the most anterior part, it is composed by a stratified 
squamous epithelium with a columnar basal layer that is attached to the 
basal lamina. The other components include the Bowman’s layer, 
stroma, Descemet’s membrane and the corneal endothelium. At the 
periphery, the cornea is separated from the sclera by a gray and 
translucent border called the limbus. 
The sclera covers the remaining ocular tissue and presents a posterior 
opening for the optic nerve. It is composed by bundles of collagen, 
fibroblasts and a moderate amount of ground substance. Contrarily to 
the cornea, the sclera is opaque and white due to the different degree of 
interweave between fibrils and the presence of emissaria that are 
responsible for the passage of arteries veins and nerves125.  
 
4.2 Uveal tract 
The uvea is the middle layer of the eye, standing beneath the sclera. It is 
composed by the iris, ciliary body (CB), and choroid. As the vascular layer 
of the ocular globe, it is responsible for the nourishment of the posterior 
segment, namely the retina. Moreover, its structures control many eye 
functions, such as the adjustment to different levels of light, 
accommodation, decrease of optical aberrations, regulation of ocular 
tension, production and drainage of aqueous humour (AqH). The 
muscular components of the uvea are present in the iris, and in the CB.  
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4.2.1 Iris  
The iris is the most anterior extension of the uveal tract. It is perforated 
at the pupil and separates the anterior from the posterior chamber. The 
iris stroma contains blood vessels and connective tissue as well as 
melanocytes and non-pigmented cells.  The functions of the iris include 
the control of retinal illumination, reduction of optical aberrations and 
improvement in the depth of focus. The iris regulates the amount of light 
reaching the retina by altering pupil diameter, and thus maximizes visual 
perception. Also, by reducing the pupil diameter it limits the light rays 
entering the optical system to the central cornea and lens avoiding more 
peripheral portions of these structures where aberrations are greater. 
When focusing close objects, a decrease in pupil diameter produces a 
pinhole effect that decreases refractive errors and improves the depth of 
focus. The modulation of pupil diameter is accomplished by the two iris 
muscles, the iris sphincter muscle and the iris dilator muscle125. 
 
4.2.1.1 Iris sphincter muscle  
The iris’ sphincter muscle (ISM) is located in the most anterior part (0.75-
1 mm from the pupilar margin) of the iris and is organized in circular 
muscle bundles126. This muscle is mainly innervated by the 
parasympathetic nervous system (PNS), being the type 3 muscarinic 
receptors127 (M3) the most abundant, followed by the M1 and M5 
types128. Despite this parasympathetic predominance, it also presents 
some innervation by the sympathetic nervous system SNS129. Other 
mediators have also been attributed a role in the kinetics of the ISM, 
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being these usually defined as the non-adrenergic non-cholinergic 
system. 
The PNS and the trigeminal system are the best characterized systems in 
the contraction of the ISM. The stimulation of M3 receptors activates 
PLC which promotes the hydrolysis of PIP2 into DAG and IP3. DAG 
inhibits K+ channels, inducing the opening of voltage -dependent L-type 
Ca2+ channels in the cellular membrane. IP3 promotes intracellular Ca2+ 
increase and free Ca2+ ions will bind calmodulin forming the calcium-
calmodulin complex. This complex activates the myosin light-chain 
kinase (MLCK) promoting myosin phosphorylation and muscle 
contraction. Other mediators of the ISM contraction include the 
substance P
130
, PACAP
130, 131
,  Calcitonin gene related peptide (CGRP)
130
, 
neurokinines132, bradykinin133, 134, PGF2α, PGE2 and PGD2
135  thromboxane 
A2
135
, ET-1
136, angiotensin II (ATII)135 and luminous stimulation137 (Figure 
5). 
The relaxation of the ISM is modulated by the inhibition of acetylcholine 
(Ach) release in the synaptic cleft or by the increase of intracellular cAMP 
or cGMP levels138-140. Mediators that inhibit Ach release include 
adenosine141, galanin and somatostatin142. VIP143, 144, adrenomedullin145, 
146  and sympathetic stimulation147, 148 lead to an increase in cAMP 
intracellular levels. Adrenomodullin
145, 146
 is able to increase cGMP 
intracellular levels, as do nitric oxide149 and natriuretic peptides A and 
C140. Finally, the specific stimulation of type B2 endothelin receptor (ETB2) 
also relaxes the ISM through prostaglandins (PGs) synthesis and NO 
release150 (Figure.6). 
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Fig. 5 Neuro-humoral pathways regulating iris’ sphincter muscle contraction. ET-1 – endothelin 1; ETB – 
endothelin receptor type B; Pg – prostaglandin; Tx – thromboxane; CGRP –calcitonin gene related 
peptide; PACAP –pituitary adenilate cyclase activator peptide; CCK-cholecystokinin; ATII – angiotensin II; 
NK2,3 – Neurokinins’ receptor type 2 or 3; AT? – angiotensin receptor unknown; PLC – phospholipase C; 
PIP2 – phosphatidylinositol 4,5-bisphosphate; IP3 –inositol trisphosphate; DAG – diacylglycerol; AA – 
arachidonic acid. From Ghrelin: production, action mechanisms & physiological effects56. 
 
 
Fig. 6 Neuro-humoral pathways regulating iris’ sphincter muscle relaxation. VIP – vasointestinal peptide; 
P Sub –substance P; ANP – auricular natriuretic peptide; CNP – cerebral natriuretic peptide; NPA – 
natriuretic peptides receptor type A; ET – endothelin; ETB – endothelin receptor type B; Pg – 
prostaglandin; Tx – thromboxane; NO – nitric oxide; NOS – nitric oxide synthase; Gc – guanylate cyclase; 
cGMP – cyclic GMP; Ac – adenylate cyclase; cAMP – cyclic AMP. From Ghrelin: production, action 
mechanisms & physiological effects
56
. 
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4.2.1.2 Iris dilator muscle  
The iris’ dilator muscle (IDM) is organized in radial muscle bundles and is 
located in the basal part of the iris126. Contrary to the ISM, the dilator 
muscle is primarily innervated by the SNS and its contraction occurs 
mainly by the stimulation of α1 receptors. The stimulation of α1 
receptors activates Gq protein with a consequent mobilization of both 
intracellular and extracellular Ca2+ leading to muscle contraction. This 
contraction is potentiated by neuropeptide Y151. Type A endothelin 
receptor (ETA) stimulation by ET-1 also lead to the contraction of this 
muscle152. 
The PNS seems to influence both the contraction and the dilation of the 
IDM. If the concentration of Ach is high, the stimulation of M3 type 
receptors leads to muscle contraction. However, if the concentration of 
Ach is low or the stimulation of the muscle is made with pilocarpine, the 
muscle relaxes153. PACAP154 and CGRP155 also promote dilator muscle 
relaxation (Figure.7). 
 
4.2.2 Ciliary body  
The ciliary body (CB) is a structure that bridges the anterior and posterior 
segments. It presents a triangular shape in transverse cross-section and 
is composed by the ciliary processes and the ciliary muscle (CM). The 
base of the CB gives rise to the iris and attaches to the scleral spur via 
longitudinal muscle fibers.  
The main functions of the CB are: the production of AqH, lens 
accommodation and maintenance of the zonules. It also plays a role in 
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both the trabecular and uveoscleral drainage pathways. The CB has been 
described as a “neuroendocrine gland”, since it participates not only in 
the secretion of AqH, but also in the synthesis of biological peptides, 
metabolism of steroid hormones156, 157. 
 
 
 
 
 
 
 
 
 
 
Fig.7 Neuro-humoral pathways regulating iris’ dilator muscle contraction and relaxation. NpY – 
neuropeptide Y; ET-1 – endothelin 1; ETB – endothelin receptor type B; Pg – prostaglandin; Tx – 
thromboxane; CGRP – calcitonin gene related peptide; PACAP –pituitary adenylate cyclase activator 
peptide; CCK-cholecystokinin; ATII – angiotensin II; NK2,3 – Neurokinins’ receptor type 2 or 3; AT? – 
angiotensin receptor unknown; PLC – phospholipase C; PIP2 – phosphatidylinositol 4,5-bisphosphate; 
IP3 –inositol trisphosphate; DAG – diacylglycerol; AA – arachidonic acid
56
. 
 
4.2.2.1 Aqueous humour production and drainage 
The secretion of aqueous humor (AqH) and regulation of its outflow are 
physiologically important processes for the normal function of the eye. 
The structure responsible for AqH production is the CB, more precisely 
the ciliary processes. The ciliary processes are localized in the innermost 
part of the ciliary body and are composed by a double layered 
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epithelium, the non-pigmented layer and the pigmented layer. The apical 
surfaces of both layers lie in apposition to each other and are joined 
together by gap junctions, leading to the formation of a syncytium158. 
The non-pigmented layer stays in contact with the AqH from the 
posterior chamber and the pigmented layer adjoins the ciliary processes 
stroma and blood vessels159-161.  
Aqueous humour is a clear fluid that provides nutrition, removes 
excretory products from metabolism, transports neurotransmitters, 
stabilizes the ocular structure and contributes to the regulation of 
homeostasis of the ocular tissues. It also plays an important role in 
pathological conditions as it allows the distribution of inflammatory 
mediators as well as drugs by the different ocular structures. There are 
three mechanisms responsible for AqH formation: diffusion, 
ultrafiltration and active secretion, being the latter the only active 
process and the major contributor for aqueous humour formation162. 
The non-pigmented ciliary epithelium is the main site responsible for 
active transport, providing passage of anions, cations and other 
molecules such as amino acids. There are two enzymes involved in this 
process: sodium-potassium-activated adenosine triphosphatase (Na+-K+ 
ATPase) and carbonic anhydrase (CA). Na+-K+ ATPase provides the energy 
for the metabolic pump which transports sodium into the posterior 
chamber. CA catalyzes the formation of H2CO3 from CO2 and H2O. H2CO3 
is will originate HCO3
- that is necessary for active secretion of aqueous 
humour. Active transport produces an osmotic gradient across the ciliary 
epithelium favoring the movement of other plasma constituents by 
ultrafiltration and diffusion
163
. After its secretion, AqH flows from the 
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posterior chamber through the pupil into the anterior chamber and then 
exits the eye by one of two ways: the conventional pathway (CP) or the 
unconventional pathway (US). 
In the CP, the AqH flows through the trabecular meshwork (TM) into the 
Schlemm’s canal and from there it is drained to the episcleral veins. 
There is a pressure gradient responsible for the flow from the TM to the 
Schlemm’s canal. In normal conditions, the production of AqH is enough 
to generate the tension needed in the TM to promote this flow in a 
passive way generating an average intraocular pressure (IOP) of about 15 
mmHg for the general population.  The TM is composed mainly of 
collagen and elastic fibers organized in lamellae164 and is responsible for 
about 75% of AqH outflow resistance
165
. This resistance can be 
influenced by the muscular tone of the CM, as it is inserted in the scleral 
spur and maintains a close relation with the TM. Thus, when this muscle 
contracts, it moves inward and anteriorly promoting a spread between 
the fibers of the TM. This leads to increased space between the fibers 
and a consequent decrease in TM resistance, promoting AqH outflow. 
On the contrary, when this muscle relaxes the resistance to AqH outflow 
increases166. The TM also possesses contractile elements that can 
regulate its tonus. The modulation of these elements may be involved in 
a regulation of the TM, and thus in the modulation of AqH outflow, 
independent from the CM164, 167. 
The other pathway involved in the drainage of aqueous humour is the 
unconventional pathway, also called the uveoscleral pathway. In this 
pathway, the AqH produced by the ciliary processes circulates normally 
to the anterior chamber but then exits through the CB and iris root to 
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the CM and suprachoroidal space being drained to the choroid or 
episcleral tissue. Contrary to the CP, the IOP is not determinant in the US 
pathway because the sclera offers little resistance to flow and the 
choroidal vessels absorb the amount of AqH delivered168. The CM, as an 
integral part of this drainage pathway, plays a pivotal role in its 
regulation. It is considered as the main site of resistance for AqH outflow 
in this route and its contraction impairs US outflow169. 
 
4.2.2.2 Ciliary muscle  
The CM has three components: an external and longitudinal portion 
(Brucke muscle), an intermediate and obliquous portion, and an internal 
and circular portion (Muller muscle). The longitudinal portion originates 
from the scleral spur and maintains a close relation with the TM.  
The CB is well supplied with nerves, both myelinated and unmyelinated 
of parasympathetic, sympathetic, and sensory types. The 
parasympathetic nerve fibers originate in the Edinger-Westphal nucleus 
and travel in the oculomotor nerve. They synapse in the ciliary ganglion 
and in a few local ganglia within the ciliary nerves, before forming 
extensive plexuses around the CM fibers170, 171. The M1, M2 and M3 type 
muscarinic receptors are all present in the CM but the M2 type is only 
present in the longitudinal portion of the muscle, indicating that 
accommodation may not be regulated by this receptor subtype172, 173. 
Besides this neuronal regulation, the CM also appears to be affected by 
other peptides. One such example is ET-1. Stimulation of HCSMCs with 
ET-1 or carbachol resulted in an increase of intracellular Ca
2+
 levels. 
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However, in the presence of norepinephrine or isoproterenol (a β-
agonist), ET-1-induced Ca2+ elevation was reduced. This effect seems to 
be related to an elevation of cAMP promoted by the adrenergic 
system174.  
The CM is responsible for the accommodation mechanism. During this 
process, CM tone influences the tension on the zonule fibers that attach 
to the lens and hence influence the lens thickness. When focusing closer 
objects the CM contracts, leading to a decrease in the tension of the 
zonules and a consequent increase in the thickness of the lens. When 
focusing distant objects, the muscle relaxes and the thickness of the lens 
decreases. 
 
4.2.3 Choroid 
The choroid is the posterior portion of the uveal tract and lies between 
the sclera and the retina. Its main function is to nourish the outer retina 
and to remove waste products. Blood supply comes from both the long 
and short posterior ciliary arteries and venous blood drains through the 
vortex veins. The choroidal circulation constitutes 85% of the blood 
circulating through the eye. Choroidal blood flow is higher than that in 
most body tissues, including the retina and brain. The choroid extends 
from the optic nerve to the ora serrata and is composed of four layers: 
the Bruch’s membrane, the choriocapillaris, a middle layer of small 
vessels (Sattler’s layer) and an outer layer of large vessels (Haller’s layer).  
The Bruch’s membrane is the innermost layer and results from the fusion 
of the basal lamina of the retinal pigmented epithelium and the 
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choriocapillaris. The choriocapillaris lies in a single plane beneath the 
Bruch’s membrane and contains fenestrated vessels facing the retinal 
pigmented epithelium (RPE). On the contrary, Sattler and Haller’s layers 
are constituted by larger and non-fenestrated vessels. Abundant 
melanocytes, some macrophages, lymphocytes, mast cells and plasma 
cells appear in the choroid stroma as well as connective tissue that 
support its structure125. 
The smooth muscle cells of the choroidal vessels walls of the choroid are 
innervated by both the PNS and SNS. The fibers from the PNS 
innervation are rich in vasodilators like VIP and NO and are responsible 
by an increase in blood flow. The SNS nervous system innervates both 
vascular an non-vascular smooth muscle cells and is responsible for 
vasoconstriction.175. Autoregulation of blood flow is the ability of the 
tissue to maintain a constant blood flow despite changes in the perfusion 
pressure. The blood flow in the ocular tissue depends on the local 
arterial blood pressure, the local venous pressure and the resistance to 
flow. A rise in IOP increases the resistance of this flow. Autoregulation of 
the choroidal circulation has been proposed but is still under debate. 
One argument against the autoregulation of the choroid lies on the fact 
that choroidal blood flow greatly exceeds the metabolic needs of the 
retina  and so even if the perfusion pressure drops significantly, retinal 
metabolism would not be compromised. Other studies however show 
that the choroid presents an autoregulation mechanism dependent on 
the IOP and that occurs only at IOP values lower than 5 mmHg, which is 
in agreement with the myogenic mechanism of regulation176.   
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4.3 Retina  
The retina is the innermost of the three layers that compose the eye and 
is the structure responsible for phototransduction. The neural retina is 
composed of six neuron types: photoreceptor cells, horizontal cells, 
bipolar cells, amacrine cells, interplexiform cells, and ganglion cells. The 
neurons are in close contact and supported by radial glial cells, the 
Müller cells.  
The retina is structurally organized in ten layers that, from the outer to 
inner retina are: RPE; rods and cones inner and outer segments; external 
limiting membrane; outer nuclear layer (nuclei of photoreceptors); outer 
plexiform layer; inner nuclear layer; inner plexiform layer; ganglion cell 
layer; nerve fiber layer (axons of ganglion cells) and finally the internal 
limiting membrane. (Figure 8) 
The RPE separates the photoreceptor outer segments from the choroid. 
This epithelium is highly pigmented and can absorb excessive light from 
reaching the photoreceptors. Furthermore, it supports and maintains the 
functions of the photoreceptor outer segments and creates a selective 
barrier between the choroidal circulation and the retina.   
The nuclei of photoreceptor cells are localized in the outer nuclear layer. 
The external limiting membrane limits these nuclei from the inner 
segments of the photoreceptors that are in the photoreceptor layer. 
Photoreceptors are responsible for phototransduction and consist of two 
different cell types, the rods that are responsible for scotopic vision and 
the cones that are responsible for photopic vision. 
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The inner nuclear layer consists of four cell types: horizontal cells, 
bipolar cells, amacrine cells and Müller cells. The horizontal and bipolar 
cells from this region form synapses with photoreceptor cells in the 
outer plexiform layer.  
The inner plexiform layer is where bipolar, amacrine and ganglion cells 
synapse. Ganglion cells and some displaced amacrine cells constitute the 
ganglion cell layer. Ganglion cells are responsible for collecting visual 
information processed in the retina and send it to the brain. Axons of the 
ganglion cells form the nerve fiber layer as they converge from all parts 
of the retina toward the optic disc. Finally, the inner limiting 
membrane is the boundary between the retina and the vitreous body 
and is constituted by astrocytes and the end feet of Müller cells. 
Glial cells are an important component of the retina. There are four 
types of glial cells present in the retina: Müller cells; astrocytes present 
mainly in the inner limiting membrane; microglial cells with phagocytic 
properties; and oligodendrocytes that surround ganglion cell axons when 
they are myelinated. Müller cells are the most abundant glial cells in the 
retina. These cells transverse the retina from the inner limiting 
membrane to the outer nuclear layer. Throughout this traject, Müller 
cells branch in order to relate with the retinal neurons, other glia or 
blood vessels. They are responsible for structural support of the neural 
retina and are also capable of insulating the neurons both chemically and 
electrically.125 
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Fig.8 Retinal functional morphology. RPE – retinal pigmented epithelium; PhL – photoreceptor layer; 
ELM – external limiting membrane; ONL – outer nuclear layer; OPL – outer plexiform layer; INL – inner 
nuclear layer; IPL – inner plexiform layer; GCL – ganglion cell layer; NFL -  nerve fiber layer; ILM – 
internal limiting membrane. Glial elements are also illustrated. Astrocytes – star-shaped cells; Müller cell 
– tall cell passing from the ILM to ONL.. 
 
5. Ghrelin in the eye 
5.1 Iris muscles 
Recently ghrelin has been attributed a role in the ocular muscle kinetics. 
More precisely, ghrelin is able to relax rabbit’s ISM and IDM5. 
In ISM precontracted with carbachol, ghrelin promotes a decrease in 
active tension in the first 1.5-3 minutes, with return to the initial active 
tension in the following 10 minutes5. Moreover, in a contraction 
mediated by electrical field stimulation, it is able to decrease the active 
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tension when compared to control177. Finally, ghrelin is also able to 
decrease ISM basal tension5, 177.  
The relaxation promoted by ghrelin in carbachol precontracted ISM does 
not seem to be dependent on GHSR-1a because des-acyl ghrelin is also 
able to promote ISM relaxation. Moreover, when antagonizing GHSR-1a 
with Lys3-GHRP-6, ghrelin’s-induced decrease in the active tension is 
more than three-fold when compared to non-antagonized receptor. 
Since GHSR-1a blockade potentiated this hormone’s effect in this 
muscle, it is possible that GHSR-1a acts as a modulator of ghrelin’s 
effect5. Relaxation of this muscle is dependent on PGs release and 
independent from NO production. Pretreatment of this muscle with 
indomethacin, a COX inhibitor, blunts ghrelin-induced relaxation, while 
pretreatment with L-nitro-L-arginine, a NOS inhibitor, has no effect on 
ghrelin’s effect5. Finally, this effect is not species dependent since the 
results have been replicated in isolated rat’s sphincter muscles both with 
ghrelin and des-acyl ghrelin5. 
Regarding the dilator muscle, ghrelin is able to decrease the active 
tension developed by rabbit’s IDM once it has been contracted with 
epinephrine. Contrary to the mechanism underlying rabbit’s ISM 
relaxation, the effect on the IDM muscle is associated with GHSR-1a, 
since pretreatment with Lys
3
-GHRP-6 abolishes ghrelin’s relaxing effect. 
Moreover, des-acyl ghrelin is unable to decrease active tension in this 
muscle5. Concerning dilator muscle basal tension, ghrelin was shown to 
have no effect on it177.  
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These data show that ghrelin is able to inhibit both cholinergic and 
adrenergic mediated contractions, being these effects possibly mediated 
by different types of ghrelin receptors5, 177. 
 
5.2 Ghrelin production in the eye 
In addition to the data mentioned above, ghrelin production in the 
ocular tissue has also been demonstrated. In 2006, a study 
demonstrated ghrelin’s production in the rat’s ocular tissue for the first 
time. Based on in situ hybridization (ISH) studies directed to ghrelin’s 
mRNA, the presence of ghrelin transcripts in the iris’ posterior 
epithelium and in the CBNPE was detected
5
. Later, the presence of 
ghrelin in the AqH of patients with glaucoma has also been verified6, 7.  
Regarding the posterior segment, Zaniolo et al. identified ghrelin and 
GHSR-1a expression in the retina. Ghrelin production was assessed by 
real time PCR and immunofluorescence (IF), showing that ghrelin is 
produced in the retina, namely in the Müller cells end-feet. As for GHSR-
1a, this group has shown through IF that it is expressed in the retina, 
mainly in Müller cells, and in the endothelial cells of the choroid8. 
 
5.3 Ghrelin-GHSR system role in ocular pathophysiology 
5.3.1 Glaucoma  
Glaucoma is a progressive neurodegenerative disease characterized by 
visual impairment as a result of optic nerve degeneration and retinal 
ganglion cell loss (RGC) loss. It is the second leading cause of blindness 
Ghrelin-GHSR system in the eye: local regulation and 
pathophysiological implications 
Chapter I - Introduction 
31 
 
 
 
worldwide and it is estimated that it will affect 79.6 million individuals by 
the year 2020178. Impairment in AqH production and/or its drainage is 
the main cause for OHT. Elevated IOP is the most common cause 
responsible for glaucoma179.  As there appears to be a relation between 
ghrelin and some of the ocular components responsible for AqH 
dynamics, ghrelin’s presence in the AqH of patients with glaucoma was 
assessed by two independent research groups (Table 1). The 
experimental conditions included control patients, patients with chronic 
open-angle glaucoma6, 7 and patients with pseudo-exfoliation glaucoma7. 
The results show that ghrelin’s levels are decreased in patients with both 
types of glaucoma compared to control. However, the plasmatic levels of 
ghrelin did not differ between normal and glaucomatous patients, 
pointing to a local mechanism of action6, 7. Nevertheless, there seems to 
be no relation between ghrelin AqH levels and the severity of the 
disease7. Regarding des-acyl ghrelin, its AqH and plasma levels in normal 
and pathological conditions were also measured6. Interestingly, neither 
AqH nor plasmatic levels of des-acyl ghrelin showed any differences 
between normal and pathologic conditions6. 
The current clinical therapies for glaucoma focus on the reduction of IOP 
by either surgical or pharmacological methods. Even though not all 
clinical scenarios of glaucoma exhibit elevated IOP, lowering IOP remains 
the only option to prevent vision loss.  
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Table 1. Comparison between ghrelin and des-octanoyl ghrelin levels in plasma and aqueous humour 
described by two different research teams
6, 7
. 
 
5.3.2 Retinopathy of prematurity (Ocular Angiogenesis) 
Recent studies have attributed a role for the ghrelin-GHSR-1a system in 
the pathogenesis of ROP. Zaniolo et al. described that ghrelin’s mRNA 
levels are decreased during the vaso-obiterative phase of the disease, 
while being two-fold increased in the vaso-proliferative phase. This 
group also demonstrated that ghrelin has a protective vascular effect 
during the vaso-obliterative phase. However, during the vaso-
proliferative phase, ghrelin’s exerts deleterious effects. Moreover, this 
effect was described as being dependent of GHSR-1a stimulation, since 
the blockage of this receptor with specific antagonists blunted ghrelin’s 
effect.8 
Ischemic proliferative retinopathies include the diabetic retinopathy (DR) 
and the retinopathy of prematurity (ROP) and are the main causes of 
blindness in the working age and pediatric populations of industrialized 
countries respectively180, 181. 
 Rocha-Sousa et al., 2009 Katsanos et al., 2011 
Control 
(pg/ml) 
Open angle 
glaucoma (pg/ml) 
Control 
(pg/ml) 
Open angle 
glaucoma 
(pg/ml) 
Pseudo-
exfoliation 
glaucoma 
(pg/ml) 
Ghrelin AqH 
levels 
14.36±8.63 7.69±3.51* 123.4 ±25,5 84.2±14.8* 88.6 ± 17.6* 
Grelin plasma 
levels 
32.12±14.87 24.88±9.81 482.2±125.4 459.8±140.3 577.5±178.4 
Ghrelin 
plasma/AqH 
levels ratio 
10.21±7.25 12.34±7.25 4.00±1.04 5.60±2.05 6.19±1.55 
Des-acyl-ghrelin 
AqH levels 
61.10±15.96 62.27±22.13 - - - 
Des-acyl-ghrelin 
plasma levels 
254,10±128,81 229.634±100,81 - - - 
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Aims 
Regarding all previously said, the aim of this work is to assess the 
presence of the ghrelin-GHSR system in the ocular tissue and its role in 
the modulation of IOP.  Specifically the objectives are: 
1. The identification of a local production of ghrelin and the 
distribution of its receptor. 
Ghrelin’s presence in AqH and its decreased levels in patients with 
glaucoma, along with its physiological role in the eye led to the 
hypothesis of the existence of a local regulatory system by ghrelin. 
Through immunofluorescence studies we characterized the 
distribution of ghrelin and its receptor in the ocular tissue. 
2.  Characterization of the ghrelin-GHSR system role in AqH drainage. 
2.1 The establishment of a consistent and reproducible model of 
OHT. 
Due to the lack of reproducibility of acute models of OHT we 
adapted a previously described model and applied it in two 
different animal models. This allowed us to study the 
hypotensive effect of ghrelin. 
2.2 The characterization of the effect of ghrelin in hypertensive 
eyes.  
Considering previous studies that implicate ghrelin in the 
physiology of the eye and in the pathophysiology of glaucoma, 
we investigated ghrelin’s hypotensive effect and its association 
with GHSR-1a. These studies were performed in two animal 
models of acute glaucoma. 
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Animals 
All animal procedures were conducted in accordance with the 
Association for Research in Vision and Ophthalmology’s (ARVO) 
statement for the use of animals in Ophthalmic and Visual Research. 
Wistar rats were purchased from Charles River Laboratories. Wistar rats 
were housed 2 per cage, in a 12 hour light-dark cycle with lights on at 8 
a.m., controlled temperature and humidity. New Zealand white rabbits 
were housed 1 per cage, in a 12 hour light-dark cycle with lights on at 8 
a.m., controlled temperature and humidity. Further description of 
animals will be provided in each protocol description. 
 
Reagents 
Imalgene 1000® was obtained from Merial (Lyon, France). Rompun® was 
obtained from Bayer (Kiel, Germany). Anestocil® was obtained from Edol 
(Lisbon, Portugal). Ghrelin and des-acyl ghrelin were obtained from 
Peptides International (Louisville, Kentucky, USA). The peptides were 
prepared in aliquots and stored at -20°C. Further description of 
particular reagents used in each protocol will be provided in protocol 
description. 
 
Statistical Analysis 
Statistical analysis was performed using SYSTAT’s Sigmaplot 11.0. Linear 
regression was used to establish a relation between the manometric IOP 
and tonometric IOP measurements. One-way ANOVA was used to test 
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differences between test groups and Student’s T-test or the 
correspondent non-parametric test was used to compare between 
control and ghrelin or des-acyl ghrelin groups in acute glaucoma studies. 
A p-value < 0.05 was considered statistically significant.   
 
1. Immunofluorescence detection of ghrelin and GHSR in 
the rat’s ocular tissue  
Reagents 
The antibodies and vascular endothelial cells marker used in the 
immunofluorescence protocols are summarized in table 2. 
Correspondent secondary antibodies used for each primary antibody are 
shown in the same column.  
 
Table 2. List of primary, and correspondent secondary, antibodies and vascular endothelial cell marker 
used in the immunofluorescence protocols. N.A – not applicable. 
 
Target Ghrelin GHSR 1 α-SMA 
Vascular 
endothelial 
cells 
Company 
H-40 Santa Cruz 
Biotechnology 
D-16 Santa Cruz 
Biotechnology 
Ab5694 Abcam 
L-5264 
Sigma-Aldrich 
Clonality Rabbit polyclonal Goat polyclonal 
Rabbit 
polyclonal 
N.A 
Dilution 1:150 1:150 1:250 1:50 
Secondary 
antibody 
Anti-rabbit Anti-goat Anti-rabbit N.A 
Fluorochrome 
conjugated 
Alexa Fluor® 488 Alexa Fluor® 488 
Alexa Fluor® 
568 
TRITC 
Host Goat Donkey Goat N.A 
Company A11008 Invitrogen A11055 Invitrogen 
A11036 
Invitrogen 
N.A 
Dilution 1:1000 1:1000 1:1000 N.A 
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1.1 Animal perfusion and tissue fixation 
Male Wistar rats weighing 200-350 g were anaesthetized with an 
intraperitoneal injection of a mixture containing ketamine chlorhydrate 
(Imalgene 1000®, 75mg/Kg) and xylazine chlorhydrate (Rompun®, 5 
mg/Kg). After deep anaesthesia had been confirmed, a thoracotomy was 
performed to expose the whole chest cavity. A catheter was inserted 
through the apex of the heart across the left ventricle and placed into 
the ascending aorta. Once the catheter had been hold in place, a cut was 
made in the right atrium and the animals were perfused with ± 150 mL 
of phosphate buffered saline (PBS, pH 7.4), at a rate between 5 and 10 
mL/min to clean the vasculature. After that, the animals were perfused 
with 400 mL of cold 4% paraformaldehyde (PFA) in PBS (pH 7.4) at a rate 
of 5 mL/min to avoid vascular dilation. The efficiency of the perfusion 
was controlled by monitoring liver color change and spontaneous 
“formalin dance”. Once perfusion had been completed, the eyes and the 
stomach were collected and placed in the same 4% PFA solution for an 
additional 1 hour period at 4
0
C. After this period, the samples were 
transferred to sucrose solutions of 10 and 20% during 30 minutes and 2 
hours at room temperature (RT) respectively and finally to a 30% sucrose 
solution containing 0.01% sodium azide during an overnight period at 
4oC. The sucrose solutions were made in PBS (pH 7.4).  
Following cryopreservation in sucrose solutions, samples were rinsed 
with PBS to remove external sucrose residues, placed in custom made 
silicon molds filled with OCT (Optimum Cutting Temperature medium, 
Neg50® Thermo Scientific Richard-Allan Scientific) at room temperature, 
left to equilibrate with OCT for 10 min and then transferred to the 
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cryostat for cryosectioning or stored at -80ºC until use. Transversal serial 
cryosections 10 µm thick were obtained and placed in Superfrost plus® 
(Thermo Scientific) slides. The slides were then stored at -80ºC or 
subjected to immunofluorescence. 
Slides were left to air-dry at room temperature for 1 hour and then 
washed in 0.1 M PBS pH 7.4 for 20 min. After that, tissue was 
permeabilized with PBS Triton X- 100 0.2% for 20 min before blocking 
non-specific binding with 3% bovine serum albumin (BSA) also in PBS 
Triton X-100 0.2%. Slides were encircled with a pap pen (Vector 
Laboratories, Burlingame, CA) and incubated overnight with primary 
antibodies at 4oC. Primary antibodies were diluted in 1% BSA in PBS 
Triton X-100 0.2%. 
Following incubation with primary antibodies, slides were washed 3 
times, 10 min each, with PBS Triton X-100 0.05% and incubated with 
secondary antibodies during 1 hour at room temperature and in the 
dark. Secondary antibodies were diluted in the same manner as primary 
antibodies. Finally, slides were subjected to 2 washes with PBS Triton X-
100 0.05%, 10 min each and one final wash with PBS for 10 min before 
mounting with Prolong Gold® antifade reagent contaning 4’,6-diamino-2-
pheylindole (DAPI) to label the nuclei. 
 
1.2 Double immunofluorescence protocols 
Double labeling experiments were performed to assess the possible co-
localization of ghrelin or GHSR with vascular endothelial cells. 
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Additionally, double labeling was also used to evaluate the possible co 
localization of GHSR with smooth muscle cells. 
Double labeling experiments regarding ghrelin or GHSR and vascular 
endothelial cells were performed according to the protocol previously 
described up to 2 initial washes following the incubation with the 
secondary antibody. After this step, slides were incubated with Lectin 
from Bandeiraea simplicifolia during one hour at room temperature and 
in the dark. Slides were then washed and mounted as already described. 
For the double labeling experiments regarding GHSR and α-SMA, a 
sequential protocol was followed. Slides were subjected to the 
immunofluorescence protocol described above, first directed to smooth 
muscle localization, through utilization anti-α-SMA and the 
corresponding secondary antibody. Afterwards, slides were subjected to 
the same protocol, including the blocking step, and incubated with 
primary anti-GHSR and corresponding secondary antibodies. In the end 
slides were washed and mounted. 
 
1.3 Controls 
Both positive and negative controls were performed. Positive controls 
for ghrelin included extracts from the rat’s stomach and positive control 
for GHSR included extracts from rat’s brains.  
Negative controls for single labeling were obtained by omitting the 
primary antibody in the incubation serum. For double labeling 
experiments, besides the omission of the primary antibodies used, 
additional negative controls were performed.  
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To control cross-reaction between primary and non-correspondent 
secondary, primary antibodies were incubated separately with the non-          
-corresponding secondary used in the double labeling experiment (i.e. 
rabbit anti-α-SMA primary with donkey anti-goat secondary and goat 
anti-GHSR primary with goat anti-rabbit secondary).  
To control cross-reaction between secondary antibodies, double labeling 
was performed normally by omitting one of the primary antibodies but 
maintaining both secondary antibodies. 
Negative control for lectin was performed by pre-incubating Lectin with 
500mM of galactose (G0625; Sigma-Aldrich) during one hour.  
Controls for autofluorescence were also performed by omitting both 
primary and secondary antibodies. 
 
 
1.4 Epifluorescence microscopy 
Epifluorescence microscopy was performed on an inverted microscope 
(Axio imager Z1; Carl Zeiss), using 10x, 20x, or 40x air objectives. Photos 
were taken with a CCD camera (Axiocam MRM), using the AxioVision® 
software version 4.8.2.  
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2. Tonometer calibration 
2.1 TonoVet® calibration in New Zealand White rabbits 
Validation of the TonoVet® rebound tonometer (Icare, Helsinki, Finland) 
was achieved by comparing tonometric measurements with those 
obtained through in vivo manometry of the anterior chamber. 
Male New Zealand White rabbits (Oryctolagus cuniculus 2.0-3.0 Kg) were 
anaesthetized with a mixture containing ketamine chlorhydrate 
(Imalgene 1000®; 0.4 g/Kg) and xylazine chlorhydrate (Rompun®; 8 
mg/Kg). Experimental protocol started once deep anaesthesia had been 
confirmed through paw pinching and absence of corneal reflex.  A 
scheme of the setup used in this protocol is represented on Figure 9.  
The setup consisted in a 3-way stopcock linked to a pressure transducer 
connected to different parts; one way was connected to a monitor 
(Datascope 2000A); another was connected to a saline solution bag; and 
the last way was connected to a 25 gauge needle used to cannulate the 
anterior chamber of the eye. IOP was manipulated by altering the height 
of the saline reservoir relatively to the eye. The alteration of the IOP was 
monitored in real time through the Datascope 2000A monitor. The IOP 
range used to calibrate the TonoVet® was between 5 and 60 mmHg 
using intervals of 5 mmHg.  
 With the setup in the closed position, the 25 Gauge needle was inserted 
through the peripheral cornea with care to avoid iris injury and as 
horizontal as possible. There was no contact between the needle and the 
cornea except for the entry point as this could alter tonometer’s 
readings in the impact point. Once the anterior chamber had been 
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cannulated, the needle position was kept fixed until the end of the 
protocol. The reservoir height was set to induce a 60 mmHg IOP. Five 
measurements were made with the tonometer in each pressure level. As 
the TonoVet® gives the mean of six measures, in each interval there was 
a total of 30 valid measurements. Only values with low or no standard 
deviation were considered. TonoVet® possesses internal calibration 
tables for some species. The “d” calibration, which is used for cat’s and 
dog’s eyes, was used in this calibration. The manometric pressure and 
the TonoVet® measurements were then compared. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Illustration of the setup used in the tonometer calibration. 
 
 
2.2 TonoVet®’s calibration in Wistar rats 
Validation of the TonoVet® rebound tonometer (Icare, Helsinki, Finland) 
was also made in Wistar rats using a similar protocol similar to that 
described above for New Zealand White rabbits.  
3-way 
stopcock and 
transducer 
Datascope 
2000A 
NaCl 0.9% 
25 G needle 
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Male Wistar rats (Rattus norvegicus 200-350g) were anaesthetized 
through an intraperitoneal injection of mixture containing ketamine 
chlorhydrate (Imalgene 1000®; 75 mg/Kg) and xylazine chlorhydrate 
(Rompun®; 5 mg/Kg). Experimental protocol started once deep 
anaesthesia had been confirmed through paw pinching and absence of 
corneal reflex. A scheme of the setup used in this protocol is represented 
on Figure 9.  The IOP range used to calibrate the TonoVet® was between 
5 and 80 mmHg using intervals of 5 mmHg.  
Five TonoVet® measurements were made in each pressure level tested. 
Only values with low or no standard deviation were considered. The “d” 
calibration was used in this calibration. The manometric and tonometric 
pressure measurements were then compared. 
 
3. Acute glaucoma model 
3.1 Acute glaucoma model in the rabbit 
To test the effect of ghrelin and des-acyl ghrelin in the IOP, acute 
glaucoma was induced by adapting a method firstly described by 
Orihashi et al. 9.  
New Zealand albino rabbits weighing 2.0-3.0 Kg were anaesthetized with 
an intramuscular mixture containing ketamine chlorhydrate (Imalgene 
1000® 0.4 g/Kg) and xylazine chlorhydrate (Rompun® 8 mg/Kg). A drop of 
4% oxybuprocaine (Anestocil®) was instilled in each eye for corneal 
anaesthesia and the basal IOP was measured with TonoVet®. After deep 
anaesthesia was confirmed, the basal IOP was measured with the 
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Tonometer and subsequently increased through the injection of a 
hypertonic saline solution (20% NaCl, 50μL) in the vitreous body of both 
eyes, with care to avoid lens injury. Either ghrelin (10-4M, n=6) or des-
acyl ghrelin (10-4M, n=6) were subconjunctivally injected in one eye 
randomly selected immediately after the intravitreous injection. The 
control group (n=7) received a subconjunctival injection containing only 
vehicle solution. Five readings were obtained every 15 minutes during 5 
hours and the mean IOP value for each time point was determined. To 
evaluate a possible systemic effect in the administration of ghrelin, the 
arterial pressure was also monitored through the insertion of a catheter 
into the central artery of the ear.  The catheter was connected to a 
pressure transducer and the transducer was connected to a monitor 
(Datascope 2000A) in order to record the mean blood pressure. 
To study the influence of NO and PGs in ghrelin’s action, a 
subconjunctival injection of either L-NAME (500 µL; 150 mg/Kg; n=9) or 
ketorolac (500 µL; 30 mg/mL; n=7) was delivered 30 min before the 
intravitreous injection of hypertonic saline solution. Control groups for 
these protocols (L-NAME n=6; Ketorolac n=6) also received a 
subconjunctival injection of L-NAME or ketorolac 30 min before the 
elevation of IOP. 
 
3.2 Acute glaucoma model in the rat 
To test the effect of ghrelin and des-acyl ghrelin in the IOP, acute 
glaucoma was induced according to the previously described protocol.  
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Briefly, male Wistar rats weighing 200-350g were anaesthetized through 
an intraperitoneal injection of a mixture containing ketamine 
chlorhydrate (Imalgene 1000® 75mg/Kg) and xylazine chlorhydrate 
(Rompun® 5 mg/Kg). A drop of 4% oxybuprocaine (Anestocil®) was 
instilled in each eye for corneal anaesthesia. After deep anaesthesia has 
been confirmed, basal IOP was measured with TonoVet® and 
subsequently increased through the injection of a hypertonic saline 
solution (20% NaCl, 16μL) in the vitreous body of both eyes with care to 
avoid lens injury. Either ghrelin (10-4M, n=13) or des-acyl ghrelin (10-4M, 
n=18) was subconjunctivally injected in one eye randomly selected 
immediately after the intravitreous injection. The control group (n=12) 
received a subconjunctival injection containing vehicle solution. Five 
readings were obtained at 5, 10 15, 20 and 30 minutes and then every 15 
minutes for a total 2 hours. In the end, the mean IOP value for each time 
point was determined.  
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1. Immunofluorescence 
1.1 Immunofluorescence for ghrelin  
The expression of ghrelin in the ocular tissue was determined through 
immunofluorescence studies. Positive signal for this peptide was 
detected in the ocular tissue, namely in the inside of the ciliary processes 
facing the ciliary body stroma (Figures 11 and 12) and in the retina 
(Figure 13). Figure 10 presents the tissue used as positive control. 
 
 
Fig. 10 Immunofluorescence for ghrelin in the gastric mucosa (positive control). A, B) Ghrelin 
immunoreactive cells (green). C,D) Negative control. Counterstain with DAPI (blue) 
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Fig.11 Immunofluorescence for ghrelin in the ciliary processes. A, B, C) Ghrelin immunoreactive cells. 
(green). D, E, F) Negative control. Counterstain with DAPI (blue) and lectin (red).  
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Fig.12 Immunofluorescence for ghrelin in the ciliary processes epithelium facing the stroma. A) Ghrelin 
immunoreactive cells (green). B) Negative control. Counterstain with DAPI (blue) and lectin (red). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13 Immunofluorescence for ghrelin in the retina. A, B) Ghrelin immunoreactive cells (green) appear 
to be localized to Müller cells (Arrow). B, D) Negative controls without primary antibodies against ghrelin 
but maintaining lectin. Counterstain with DAPI (blue) and lectin (red). GCL – ganglion cell layer; INL – 
inner nuclear layer; ONL – outer nuclear layer; PhL – photoreceptor layer. 
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1.2 Immunofluorescence for GHSR  
The expression of GHSR in the rat’s ocular tissue was assessed by 
immunofluorescence. GHSR is expressed in the TM (Figure 17), ciliary 
processes (Figures 15 and 17), corneal epithelium (Figure 16), iris, (Figure 
15 and 18), retina and choroid (Figure 19). When assessing GHSR 
localization relative to the ocular contractile elements, although these 
structures did not co-localize, positive signal for receptor expression was 
present in the base of the ciliary muscle, a region comprehending the TM 
and the transition between the ciliary body and the sclera. Positive 
controls are shown in Figure 14. 
 
 
Fig. 14 Immunofluorescence for GHSR in transverse sections of the brain (positive control). A, B) Positive 
signal for GHSR in the arcuate nucleus (green). C, D) Negative control. Counterstain with DAPI (blue). 
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Fig.15 Immunofluorescence for GHSR in the ciliary body. A, B) Positive signal for GHSR in the ciliary 
processes stroma, iris and in the ciliary muscle area (green). C, D) Negative control. Counterstain with 
DAPI (blue).  
 
 
 
 
 
 
 
 
Fig.16 Immunofluorescence for GHSR in the cornea. A) Positive signal for GHSR in the corneal epithelium 
(green). B) Negative control. Counterstain with DAPI (blue). 
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Fig.17 Double Immunofluorescence for GHSR and α-SMA or lectin. Images on the right side are a 
magnified view (20X) of the correspondent image on the left side. A, D) Double labeling for GHSR (green) 
and lectin (red). A strong expression of GHSR is found on the TM. There is co-localization with vascular 
endothelial cells in the ciliary processes. B,E) Double labeling for GHSR and α-SMA. There is no co-
localization of GHSR with the ciliary muscle. However, there is a strong expression in the TM and in the 
border of the CM with the sclera. C,F) Negative controls. Counterstain with DAPI (blue).  
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Fig.18 Immunofluorescence for GHSR in the iris. A, B) Positive signal for GHSR is distributed through the 
entire iris but appears to be more intense near the posterior epithelium (green). C, D) Negative control. 
Counterstain with DAPI (blue).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.19 Immunofluorescence for GHSR in the retina. A) Double labeling for GHSR (green) and vascular 
endothelial cells (red). GHSR is expressed in the inner plexiform layer but does not colocalize with 
vascular endothelial cells in this area. B, C) Double immunofluorescence for GHSR (green) and α-SMA 
(red). GHSR is abundantly expressed in the retina. C) Most of the expression is localized in the inner 
plexiform layer. B) This area is closer to the fovea and shows a strong expression in the photoreceptor 
area. There is also expression for GHSR in the choroid (arrow). D) Negative control. Counterstain with 
DAPI (blue). 
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 2. Tonometer calibration  
Both in the rabbit and in the rat, tonometer measurements 
underestimated the manometric pressure measurements as shown 
(Figures 20 and 21). A linear relation was established between the 
manometric IOP and the IOP given by the tonometer. In the rabbit 
(n=14), the determination coefficient (R2) for this relation was 0.87 and 
the slope was 0.750. In the rat (n=11), these values were 0.98 and 0.459 
respectively. 
To establish a more accurate relation with real IOP, all tonometric 
measurements obtained during the intraocular hypertension protocols 
were adjusted according to the following equations: 
 
Rabbit: 
               
(                    )
    
            
                           
Rat: 
               
(                    )
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Fig. 20 Linear correlation established for the rabbit between the manometric IOP and the IOP measured 
with the TonoVet®. 
 
 
Fig. 21 Linear correlation established for the rat between the manometric IOP and the IOP measured 
with the TonoVet®. 
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3. Acute glaucoma model 
The method used in glaucoma induction was an adaptation from the 
model previously described by Orihashi et al9. Data regarding the rabbit 
experimental protocols are summarized in table 3 as mean ± SEM. In this 
animal model, the injection of hypertonic saline promoted a consistent 
increase of the IOP that was observed at 15 min post-injection. The 
increase in intraocular pressure did not present any statistically 
significant difference between the different groups (p = 0.962). Thus, an 
increase of 559.4 ± 125.25% was observed in the control group, of 
479.90 ± 27.0% in the ghrelin group and of 463.37 ± 56.01% in the des-
acyl ghrelin group. In the control group, elevated IOP was maintained 
during 150 min when IOP value was 41.47 ± 3.56 mmHg. After this 
period, the IOP slowly began to decrease returning to baseline values 
300 min post injection.  
In the rat, the injection of hypertonic saline also promoted a consistent 
increase in the IOP without any statistical difference between groups 
(p=0.192). This elevation was noticed at 5 min post-injection and 
corresponds to an increase of 663.02 ± 90.48% in the control group, 
508.80 ± 73.44% in the ghrelin group and 559.56 ± 78.07% in the des-
acyl ghrelin group. In this model, the control group maintained elevated 
IOP during a period of 30 min, returning to baseline values 120 min after 
the intravitreous injection. 
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Table 3 Comparison of both animal models of OHT. Basal IOP was measured in all animals after deep 
anaesthesia had been confirmed and immediately before the induction of OHT.  
 
4. Effects of ghrelin and des-acyl ghrelin in IOP 
4.1 Rabbit model of OHT 
In the rabbit, subconjunctival injection of ghrelin promoted a decrease of 
the IOP when compared to control. This decrease reached statistical 
significance between 90 and 165 min. The maximal IOP decrease 
occured at min 135 and corresponded to a negative difference of 18.98 ± 
5.22 mmHg (43.8 ± 12.05%) when compared to control. Des-acyl ghrelin 
was not able to significantly decrease the intraocular pressure. The 
maximal decrease promoted by des-acyl ghrelin of -7.29 ± 3.70 mmHg 
also at min 135 and accounts for a decrease of 16% ± 8.52% when 
compared to control. Moreover, in the des-acyl ghrelin group IOP values 
 
Rabbit Rat 
Basal IOP 
(mmHg) 
IOP increase 
at 15 min 
(mmHg) 
Peak IOP 
(mmHg) 
Basal IOP 
(mmHg) 
IOP increase 
at 5 min 
(mmHg) 
Peak IOP 
(mmHg) 
Control 9.965±1.855 34.82±4.12 45.62±2.52 12.34±1.14 59.28±4.26 71.69±4.22 
Ghrelin 9.33±0.74 34.98±2.7 44.84±3.32 14.41±1.28 49.63±4.31 64.04±4.61 
Des-acyl 
ghrelin 
10.71±1.13 36.09±3.11 46,80±3.06 14.021±1.29 49.70±3.61 63.72±2.83 
L-Name 14.71±0.63 28.98±1.94 44.66±5.58 - - - 
L-NAME + 
ghrelin 
12.26±1.04 30.87±3.19 50.01±2.90 - - - 
Ketorolac 15.46±1.20 25.2±3.47 47.33±2.31 - - - 
Ketorolac + 
ghrelin 
11.83±0.9 36.95±5.18 51.60±3.49 - - - 
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did not return to baseline values contrary to what happened both in 
ghrelin and control groups. 
 
 
 
 
 
 
 
 
 
 
Fig. 22 Effect of ghrelin in rabbits’ hypertensive eyes. *p ≤ 0.05 
 
 
 
 
 
 
 
 
 
Fig. 23 Effect of des-acyl ghrelin in rabbits’ hypertensive eyes. *p ≤ 0.05 
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4.1.1 Evaluation of the systemic influence in ghrelin’s 
hypotensive effect 
To evaluate the influence of a possible systemic response to ghrelin’s 
administration on its intraocular hypotensive effect, the arterial pressure 
was monitored through the catheterization of the central artery of the 
ear. Data concerning the mean arterial pressure are summarized in table 
4. The results suggest that the influence of ghrelin in the IOP is not 
influenced systemically but is due to a local mechanism of action. 
 
 Mean arterial pressure 
Initial 15 min P value 
Ghrelin 58.3±5.7 58.2±6.0 0.985 
Des-acyl ghrelin 72.7±4.4 69.4±5.4 0.486 
 
Table 4 Data regarding mean arterial pressure in rabbits injected with ghrelin or des-acyl ghrelin. 
 
4.1.2 Effects of L-NAME and Ketorolac in ghrelin’s action 
To study the influence of NO and PGs on ghrelin’s effect, L-NAME or 
ketorolac were subconjunctivally injected 30 min before intraocular 
hypertension induction. 
Ghrelin’s action was completely blunted in the presence of either L-
NAME or ketorolac. In the presence of L-NAME, IOP values in the 
presence of ghrelin were overall higher when compared to control. At 
min 165, the IOP in the ghrelin group was in fact 10.40 ± 4.54 higher than 
in the control group (Figure 24). When ketorolac was administered, the 
IOP pattern in the ghrelin group resembled that of the control group 
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(maximal decrease of 4.58 ± 3.40 at 225 min), demonstrating that 
ghrelin’s effect was blunted (Figure 25).  
 
 
 
 
 
 
 
 
 
Fig. 24 Effect of L-NAME in ghrelin’s action in rabbits’ hypertensive eyes.  
 
 
 
 
 
 
 
 
Fig. 25 Effect of Ketorolac in ghrelin’s action in rabbits’ hypertensive eyes. 
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4.2 Rat model of OHT 
In the rat, subconjunctival ghrelin injection also promoted a decrease on 
the IOP when compared to control, reaching statistical significance 
between 10 and 25 min (Figure 26). This decrease was maximum at 20 
min and corresponded to a negative difference of 21.24 ± 4.13 mmHg 
(33.28 ± 6,47%) when compared to control. 
Contrary to the observed in the rabbit, in the rat des-acyl ghrelin 
promoted a decrease in the IOP. This decrease was similar to that of 
ghrelin but occurred in a broader time range (between 5 and 45 min) 
(Figure 27). The maximal decrease promoted by des-acyl ghrelin was 
registered at 30 min and accounted for –21.09 ± 3.94 mmHg (39.09 
±7.30%) in IOP when compared to control.  
 
 
 
 
 
 
 
 
 
 
Fig. 26 Effect ghrelin in rats’ hypertensive eyes. *p ≤ 0.05. 
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Fig. 27 Effect of des-acyl ghrelin in rats’ hypertensive eyes. *p ≤ 0.05 
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1. Localization of Ghrelin and GHSR in the rats’ ocular tissue 
Recent studies have implicated ghrelin in the ocular physiology5, 177 as 
well as in the pathophysiology of glaucoma6, 7 and ROP8. Ghrelin’s mRNA 
has been identified in the anterior segment and this hormone is also 
present in the AqH. Interestingly, ghrelin’s levels in the AqH of glaucoma 
patients are decreased and this decrease is not accompanied by a similar 
alteration in plasmatic levels
6, 7
. Taken together, these data suggest a 
local role for ghrelin in the anterior segment. Regarding GHSR presence 
in the anterior segment, no data had previously been described. 
Both ghrelin and GHSR-1a localization in the posterior segment had 
already been characterized. Ghrelin is expressed in the retina, 
particularly in Müller cells end-feet. GHSR-1a is expressed in the retina as 
well, namely in Müller cells like ghrelin, but also in retinal endothelial 
cells. Moreover, the ghrelin GHSR-1a system has been implicated in the 
pathophysiology of oxygen-induced ROP. In this condition, this system 
has been proved beneficial in the vaso-obliterative phase and 
deleterious in the vaso-proliferative-phase8.  
We investigated the presence of ghrelin and GHSR in the rat’s ocular 
tissue by immunofluorescence. Our results demonstrate the expression 
of ghrelin in the anterior and posterior segments of the rat’s eye. 
In the anterior segment ghrelin’s expression was confined to the ciliary 
processes, particularly in the epithelium and in the stroma. In the stroma 
ghrelin did not co-localized with vascular endothelial cells marker. These 
results indicate a local production of ghrelin by the ciliary processes of 
normal Wistar rats, which is in agreement with previous studies where 
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ghrelin’s mRNA was identified in the non-pigmented ciliary epithelium5. 
Based on the present study results, it is not possible to ascertain 
ghrelin’s localization to the non-pigmented ciliary epithelium. However, 
because ghrelin’s mRNA was identified in this type of epithelium, and 
also because the non-pigmented epithelium is the main site of AqH 
production by active secretion, it is logical to infer that ghrelin’s 
expression is confined to this epithelium.  
Rocha-Sousa et. al also found ghrelin’s mRNA in the iris’ stroma5. In the 
currently presented studies we were not able to find ghrelin’s expression 
in the iris. A similar situation has been described in the case of some 
prostatic carcinomas, where ghrelin mRNA was detected but the protein 
presence was not confirmed by immunohistochemistry
182
. It is possible 
for cellular regulation at the protein level to be involved in this 
discrepancy.  
In the posterior segment ghrelin’s expression was detected in the retina. 
Positive signal for ghrelin appeared throughout the retina in a pattern 
most likely corresponding to the localization of Müller cells. These results 
are in agreement with a recent study where ghrelin was identified in the 
retina, particularly in Müller cells end-feet8. However, in our study we 
did not perform double-labeling with Müller cells specific marker Cellular 
Retinaldehyde-Binding Protein (CRALBP) and therefore cannot state that 
ghrelin’s expression is indeed located in these cells. Further evaluation is 
needed to confirm these data. Nevertheless, these results point to a role 
for this peptide in the posterior segment. Regarding the choroid, there 
was no positive signal for ghrelin’s expression. 
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Focusing now on GHSR, its expression was detected throughout the 
ocular tissue. The major expression sites for GHSR are the ciliary 
processes, TM, corneal epithelium, iris and choroid.   
In the anterior segment a marked expression is found in the ciliary 
processes stroma and in the TM. The presence of GHSR in these 
locations may indicate a role in the regulation of the production of 
aqueous humour or in TM functionality.  
Active secretion is the main process responsible for the production of 
AqH. There are two enzymes abundantly present in the NPE that are 
responsible for this process: Na+-K+-ATPase  and CA183. NO is a well-
known mediator that has been proved to reduce IOP184. Moreover, 
cGMP-NO pathway is responsible for a reduction in aqueous humour 
production by inhibiting Na+-K+ ATPase activity in the NPE185, 186. The 
stimulation of GHSR-1a can activate the Gc pathway, with formation of 
cGMP and consequent NO release53, 54. In our study we co-localized 
GHSR with VECs in the ciliary processes. These data suggest that this 
receptor may play an important role in the physiology of this tissue by an 
autocrine or paracrine regulation.  
The TM is one of the major structures responsible for AqH drainage. Its 
relation with the CM is responsible for the modulation of AqH drainage. 
However, there have been described contractile elements in the scleral 
spur, which present some characteristics of both vascular smooth muscle 
cells and myofibroblasts. These contractile elements probably function 
independently from those of the CM and are involved in the regulation 
of trabecular outflow167, 187. Once relaxation of the TM contractile 
elements occurs, there is a decrease in trabecular resistance, with a 
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consequent increase in AqH outflow164, 188. NO and the PKC pathway 
have been involved in the modulation of isolated TM strips tonus. NO led 
to the relaxation of TM strips 189, while PKC promoted their 
contraction190. As mentioned above, GHSR-1a stimulation can promote 
NO release through cGMP formation or activate the PKC pathway. Since 
the inhibition of Na+-K+ ATPase by NO reduces AqH formation, one can 
speculate that this reduction together with the relaxing effect of NO in 
TM cells may lead to a reduction in IOP by a synergic mechanism. On the 
other hand, if PKC signaling is simultaneously activated, there might 
occur a decrease in the trabecular outflow. These data support the 
hypotheses of GHSR-1a involvement in the regulation of AqH dynamics 
and may present an interesting therapeutic target for glaucoma.  
Still regarding the anterior segment, a strong expression for GHSR was 
found in the corneal epithelium. The cornea is the first refractive 
structure of the eye and is also a barrier between the outer environment 
and the interior of the ocular globe. The corneal epithelium is composed 
of three cell types: basal cells, in which mitosis occurs; wing cells that 
result from the differentiation and migration of daughter cells originated 
by basal cells mitosis; and a more external layer of completely 
differentiated cells that degenerate and are sloughed from the 
epithelium. The corneal epithelium is continuously renewed and 
interacts with the tear film in order to maintain a smooth optical surface. 
This renewal is supported by the migration of basal cells from the limbus 
to the center of the cornea. 
The regulation of the corneal epithelium plays a central role in cornea 
healing, responding promptly to injury. Cell migration and proliferation 
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are the two main processes responsible normal regulation of the 
epithelium and its response to injury. These mechanisms are under 
control of a great variety of growth factors and signaling pathways191.  
Signaling pathways involved in this regulation include the MAPK signaling 
cascade192, and intracellular mediators like PKC193, 194 and cAMP195. Upon 
stimulation, GHSR-1a presents the capacity to trigger these signaling 
pathways. The expression of GHSR in corneal epithelium may therefore 
indicate a possible role for this receptor in the maintenance of the 
corneal epithelium functional structure.  
In the iris, GHSR-1a presents a moderate expression particularly near the 
posterior epithelium. The role of GHSR-1a in the contraction of the iris’ 
sphincter and dilator muscle has previously been studied
5
. In these 
studies, GHSR-1a was shown to be involved in the relaxation of the 
dilator muscle, but not the sphincter. Moreover, ghrelin’s mRNA was 
identified in the iris’ stroma, particularly near the posterior epithelium. 
Regarding the already proved effects of ghrelin-GHSR-1a system in the 
muscular kinetics, it is possible that a local regulatory loop between 
ghrelin and GHSR-1a occurs in this tissue. However, since ghrelin’s 
expression in the iris was not detected in the present study, further 
investigation is needed in order to clarify this situation.  
Finally, GHSR is also expressed throughout the choroid, being these data 
consistent with previous studies that had already characterized GHSR 
expression in the vascular layer8. However, contrary to our data, in 
previous studies this receptor co-localized with endothelial cells. The 
presence of this receptor in the choroid and the presence of ghrelin in 
Müller cells of the retina may suggest a a local regulation loop regarding 
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this tissue. However, further studies are needed to evaluate this 
hypothesis and to determine the precise localization of GHSR.  
 
2. Validation of the TonoVet® rebound tonometer 
Two animal species were used to develop an acute glaucoma model, the 
rabbit and the rat. To measure the intraocular pressure in these animal 
models we used a commercial rebound tonometer used in veterinary, 
the TonoVet®. This tonometer was chosen because it does not require 
special training and the IOP is measured easily, rapidly and in a non-
invasive way, and thus causing no discomfort to animals. In fact, the 
impact of the light-weight probe of the TonoVet® in the cornea is so 
despicable that it does not trigger corneal reflex. 
TonoVet® has been designed for veterinary use and calibrated for dogs, 
cats and horses. Therefore, the validation of the tonometer by 
establishing a linear relation with manometric values allows a more 
accurate appreciation of the IOP, which is particularly important when 
using the tonometer in different species such as the rabbit and the rat.  
 Both in the rabbit and in the rat, a relation between TonoVet®’s 
measurements and IOP measured by in vivo manometry was established. 
The TonoVet® clearly underestimates the IOP in both animals models. In 
the rabbit, this result is in agreement with other tonometers196-199, 
namely the Tono-pen XL®. Moreover, the underestimation exhibited by 
the TonoVet® becomes more evident with IOP increase, which is also in 
accordance with other reports199. However, TonoVet®’s accuracy seems 
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to vary according to species. Thus, in monkeys and cats, TonoVet® 
proved to have a good correlation with manometric values200, 201.  
In our study we also validated TonoVet®’s measurements in rat. In this 
animal, when compared to our validation in the rabbit, the 
underestimation of the IOP by the TonoVet® was much more 
pronounced and more evident in high pressure values. However, for the 
manometric values of 5 and 10 mmHg exceptionally, the rat’s tonometric 
measurements are overestimated when compared with the rabbit’s. 
To our knowledge this was the first evidence of successful utilization of 
TonoVet® in the rat. Rebound tonometry has an error associated with 
central corneal thickness. It has been reported that when measuring IOP 
with rebound tonometry, thicker corneas result in overestimated 
values202, 203. Because the rabbit presents a thicker cornea than the rat204, 
it is it possible that the difference encountered between the values is 
associated to this difference. Moreover, our correlation with in vivo 
manometry was performed using the internal calibration for cats and 
dogs. Thus, because cats and dogs have similar central corneal 
thickness,205, 206 and this thickness is greater than the rabbits, it 
strengthens our hypothesis.   
The same company who fabricates TonoVet® also offers another 
tonometer specifically designed for the use in rodents, the TonoLab®. 
There have been discrepancies regarding TonoLab®’s accuracy in rats. 
Two independent studies in Wistar rats reported a very good correlation 
between TonoLab®’s measurements and manometry207, 208. However, a 
study by Morrison et al. in Brown Norway rats described an 
underestimation of IOP by the TonoLab® when compared to manometry. 
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Moreover, this study also classified the TonoLab® as non-sensitive for 
measures below 20 mmHg209. Our findings with the TonoVet® in the rat 
resemble most the latter study. In fact, although we did not find a 
plateau below 20 mmHg, we noticed that most of TonoVet® readings 
below 10 mmHg failed, requiring many attempts in order to obtain a 
valid measurement. It is possible that due to the small size of the rats 
eye when compared to the rabbits, at low pressures the probe is not 
sensitive enough to perform accurate measurements. Moreover, this can 
be an explanation for the discrepancies found at 5 and 10 mmHg in the 
rat, which are the only overestimated values when compared with the 
rabbit. Fortunately this was not a limitation to our study because rat’s 
normal IOP is around 17-18 mmHg207, 210. 
 
3. Animal model of OHT 
To study the effects of ghrelin and des-acyl ghrelin in the acute elevation 
of IOP, we adapted a previously described model
9
. Although several 
other models have been used to transiently increase the IOP211-213, we 
were not able to reproduce them in a consistent way.  On the contrary, 
when testing the model described by Orihashi et al9 we obtained similar 
results (data not shown).  
 
The injection of 0.1 mL of 5% NaCl in the vitreous body of rabbit eyes 
produces an increase in the IOP that is evident in the first 15 min post-
injection. Ocular hypertension is maintained for a period of 90 min and 
then starts to decrease slowly, maintaining IOP above normal values 
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until min 180 and returning to baseline values between 240 min and 300 
min9, 214, 215. In the rabbit, the modification of the saline solution’s 
concentration from 5% to 20% and the reduction of the volume injected 
IV from 100µL to 50 µL conducted a more sustained increase in the IOP. 
This modification did not alter per se the peak IOP at 15 min (44.31 ± 
3.15 mmHg vs 49.7 ±2.5 mmHg216; 45.0 ±2.2 mmHg214), promoting an 
increase of 34.98 ± 2.7 mmHg from baseline levels, similar to the values 
reported by Orihashi9. However, this modification produced an evident 
sustain in ocular hypertension that prolonged until min 150. After this 
time, the pressure slowly started to decrease and remained above 
normal values until min 240, reaching baseline values by min 300. 
The same model was used in the rat, with a reduction of the volume 
injected from 50 µL to 16 µL. The amount of volume injected was based 
in the volume of the rat’s eye when compared with the rabbit’s. The 
intravitreous injection of hypertonic saline in this animal also promoted a 
sustained increase in the IOP. When compared to the rabbit, this 
increase is much more pronounced and evident as soon as 5 min post-
injection (59.28 ± 4.26 mmHg). Indeed, at 15 min this model still exhibits 
a marked difference (44.31 ± 3.15 mmHg in the rabbit vs 59.35 ± 4.72 
mmHg in the rat). However, ocular hypertension in this animal model 
remained constant only until 30 min post injection, then starting to 
decrease, reaching baseline values after 120 min. Nevertheless, 
hypertensive values were observed until min 60. The consistency of 
these results indicates the stability and high reproducibility of this model 
for the induction of intraocular hypertension.  
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The mechanism that explains the elevation of IOP in this model is the 
osmolarity gradient created dependent on salt concentration9. When 
injected, the salt deposits on the vitreous body and a gradient is 
established allowing water entrance to the posterior segment. This 
volume increase in the posterior segment pushes the lens anteriorly and 
increases the IOP. Therefore, by increasing the salt concentration from 
5% to 20% we were able to increase the gradient and maintain ocular 
hypertension for a longer period of time. Nevertheless, it is possible that 
the volume increase in the posterior segment can lead to an anterior 
displacement of the iris and as well as a rotation in the CB, with 
subsequent shallowing of the anterior chamber. This phenomenon is 
known as malignant glaucoma217.  
 
4. Effects of ghrelin and des-acyl ghrelin in animal models 
of OHT 
Ocular hypertension is the main controlled etiologic factor for glaucoma 
and the reduction of IOP remains the best and only proved treatment. 
Ghrelin has been implicated in the pathophysiology of glaucoma6, 7. Its 
AqH levels are decreased in patients with different types of glaucoma, 
while ghrelin’s plasmatic levels remain normal. Plasma and AqH levels of 
des-acyl ghrelin are also normal in these patients6. Moreover, ghrelin has 
been shown to relax both the iris’ sphincter and dilator muscle and 
ghrelin’s mRNA has been identified in the eye5. Cuncurrent with all 
previously said, this work enhances the hypothesis of a role for ghrelin in 
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the pathophysiology of glaucoma, since it demonstrates the lowering 
effect of ghrelin in the IOP of hypertensive eyes.  
Both in the rabbit and in the rat, ghrelin is responsible for a significant 
decrease in the IOP of hypertensive eyes. In the rabbit, this effect was 
maximum at 135 min post-elevation of IOP and corresponded to a 
decrease of 18.98 ± 5.22 mmHg (43.81 ± 10.81%) when compared to 
control. In the rat, the maximum decrease in the IOP obtained with 
ghrelin was at 20 min and corresponded to a difference of 21.24 ± 4.13 
mmHg (33.28 ± 6.47%). 
The subconjunctival route was used to deliver both ghrelin and des-acyl 
ghrelin to the eye. This route relies on sclera permeability for the 
diffusion of drugs to the eye. Nevertheless, this route poses a risk for 
systemic effects. We evaluated a possible systemic influence in the 
hypotensive effects of these peptides. Both ghrelin and des-acyl ghrelin 
are known potent vasodilators105, 218. Indeed, when injected systemically, 
ghrelin decreases the mean arterial pressure by 12 mmHg and the 
hypotensive effect is evident five minutes after injection. In our studies, 
neither ghrelin nor des-acyl ghrelin were capable of decreasing the mean 
arterial pressure. This indicates that the hypotensive effect of ghrelin in 
the IOP is not systemically mediated. 
The current therapeutic options to decrease IOP in primary open-angle 
glaucoma include α2-adrenoreceptor agonists, β-blockers, carbonic 
anhydrase inhibitors (CAIs) and hypotensive lipids (prostaglandin 
analogs). All these drugs show a less effective decrease in the IOP than 
ghrelin. In growing order of efficacy, Brinzolamide and Dorzolamide 
(CAIs) decrease IOP 17 and    22 % respectively, Brimonidine (α-2 agonist) 
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decreases IOP 25%, Betaxolol and Timolol (β-adrenergic blockers) 
decrease 23 and 27% respectively and finally Travoprost, Latanoprost 
and Bimatoprost (prostaglandin analogs) that decrease 31, 31 and 33% 
respectively219. 
Glaucoma is not accompanied by a decrease in des-acyl ghrelin’s levels. 
However, some studies have attributed biological effects to des-acyl 
ghrelin similar to ghrelin in some organs.  Similarly to ghrelin, we tested 
des-acyl ghrelin effect in both rabbit and rat’s hypertensive eyes. In the 
rabbit, contrary to ghrelin, this peptide failed to significantly decrease 
the IOP. The maximum decrease achieved by this peptide was 7.29 ± 
3.70 mmHg (16.80 ± 8.52%) at 135 min post-elevation of the IOP. 
Moreover, des-acyl ghrelin’s eyes were not able to return to baseline 
levels of IOP after 300 min and had a significant increase in IOP when 
compared to control. Interestingly, in the rat des-acyl ghrelin was able to 
significantly decrease the IOP in hypertensive eyes similarly to ghrelin. 
The maximum decrease achieved by this peptide was at 30 min and 
corresponded to a decrease of 21.09 ± 3.94 mmHg (39.09 ± 7.3%) when 
compared to control. 
Ghrelin and des-acyl ghrelin are similar peptides with the exception that 
des-acyl ghrelin lacks the acyl group at Ser 3 and therefore it is unable to 
bind GHSR-1a. Ghrelin’s hypotensive effect in the rabbit seems to be 
mediated by GHSR-1a because des-acyl ghrelin failed to decrease the 
IOP. However, in the rat this effect was not concurrent as des-acyl 
ghrelin was also able to decrease the IOP with the same potency as 
ghrelin. There is a great deal of uncertainty regarding ghrelin and des-
acyl ghrelin’s mechanism of action. On the one hand, both peptides have 
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been shown to have opposing effects in numerous systems122-124. On the 
other hand, there also have been described similar effects78, 81, 119, or no 
effects for des-acyl ghrelin when compared to ghrelin3, 107. In the eye, 
des-acyl ghrelin has also been shown to have different effects depending 
on the muscle. Thus, in the iris’ sphincter it is able to promote relaxation, 
whereas in the dilator it has no effect5. Moreover, ghrelin was shown to 
exert effects in tissues were GHSR-1a was not present220, 221. All this data 
lead to the hypothesis of other receptors responsible for ghrelin and des-
acyl ghrelin’s actions. CD36, a multifunctional scavenger receptor with 
widespread distribution has been pointed as one of the receptors that 
may be indirectly involved in ghrelin’s actions due to its affinity to bind 
growth hormone secretagogues222, 223. However, this hypothesis still 
requires further studies. Another possible explanation is that possibly 
the different hypotensive effect of des-acyl ghrelin, as well as the cellular 
pathways activated, in these animal models is species dependent. In the 
rabbit the effect seems to be mediated by GHSR-1a while in the rat it is 
possible that the effect is associated to another receptor that remains 
unknown.  
 
4.1 Role of nitric oxide and prostaglandins in the effect of ghrelin 
Nitric oxide and prostaglandins are two of the mediators involved in 
some of ghrelin’s actions53, 224.In addition, in the eye ghrelin is 
responsible for a relaxation of the iris’ sphincter muscle and this effect is 
dependent on prostaglandins’ synthesis but independent from NO 
release5.  Because ghrelin has shown a hypotensive effect, we decided to 
investigate the influence of NO and prostaglandins. In the rabbit, the 
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inhibition of NOS or COX with L-NAME or ketorolac completely blunted 
ghrelin’s effect.  In the L-NAME group, the maximum decrease in IOP 
achieved was 0.55 ± 2.90 mmHg (1.25 ± 6.65%) at 20 min, while in the 
ketorolac group it was 4.58 ± 3.40 mmHg (15.48 ± 11.50%) at 225 min. 
These results suggest the involvement of these two mediators in 
ghrelin’s effect in the rabbit animal model.  
Nitric oxide is an important mediator in ocular physiology and pathology. 
It can be synthetized by three isoforms of NOS: neuronal NOS (nNOS), 
endothelial NOS (eNOS) and inducible NOS (iNOS). The first two are 
constitutive enzymes and the latter is mainly expressed following 
exposure to pro-inflammatory stimuli. Both nNOS and eNOS are active in 
the anterior segment of the eye, particularly eNOS. Moreover, eNOS 
activity is enriched in sites responsible for AqH outflow regulation such 
as the CM, the TM and the Schlemm’s canal225. In addition, NO has been 
implicated in the reduction of IOP184, 226. Regarding the rabbit animal 
model, ghrelin’s hypotensive effect was shown to be related to NO 
release. Ghrelin has been shown to phosphorylate eNOS and lead to the 
synthesis of nitric oxide53. Nitric oxide in its turn is responsible for an 
intracellular increase in cGMP that is responsible for an IOP lowering 
effect184, 227.  This increase in cGMP can induce the relaxation of the CM 
and increase the US pathway promoting a decrease in IOP. Another 
explanation relies on the fact that the TM has intrinsic contractile 
elements164 that can be relaxed by NO. This would promote a decrease in 
the trabecular tension and promote the drainage of AqH. These results 
are in concordance with other studies where some compounds 
promoted an IOP decrease dependent on NO synthesis
214-216
. 
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Prostaglandins are hormones that play an important role in the ocular 
tissue. They are produced by cells related with the AqH outflow pathway 
and have been suggested as having a role in the regulation of AqH 
outflow228, 229. Various prostaglandins’ receptors have also been located 
in the ocular tissue230, 231. Moreover, PGF2α analogs such as Latanoprost, 
Bimatoprost and Travoprost are currently the most effective drugs in the 
treatment of glaucoma219. These drugs increase US outflow first by 
relaxing the CM and then by activating matrix-metalloproteinases 
(MMPs) which in long-term are responsible for the degradation of 
extracellular matrix within the CM and a consequent increase in the US 
pathway232-235. However, some studies indicate that MMPs are also 
expressed by TM and that their activation may be involved in an increase 
in the outflow by this route236-239. Cyclooxygenases are involved in the 
pathway of prostaglandin formation. They are expressed in the ocular 
tissue240, 241 and in our studies the blockage of these mediators with 
ketorolac abolished ghrelin’s relaxing effect. The release of 
prostaglandins promoted by ghrelin is known and has already been 
verified in the ocular tissue5. As said above, PGF2α analogs are 
responsible for an increase US outflow. These act primarily through FP 
receptors and Gq signaling increasing intracellular Ca
2+ 242. Another type 
of prostaglandin, PGE2, can bind to 4 subtypes of receptor (EP1, EP2, EP3 
and EP4). EP1 and EP3 receptors promote an increase in intracellular 
Ca2+ and lead to contraction. EP3 is also able to inhibit cAMP 
formation242. However, the stimulation of the EP2 in the CM activates 
the Gs and triggers a signaling cascade that leads to an increase in 
intracellular levels of cAMP. This increase is responsible for a relaxation 
of the CM and a consequent increase in the US outflow243. Regarding the 
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trabecular outflow, a recent study showed that the stimulation of the 
EP4 receptor present in the Schlemm’s canal improved this route244. The 
mechanism responsible for prostaglandins’ reduction in IOP is still 
unclear. The fact that PGF2α analogs act through FP receptors and Gq 
signaling is not concordant with the theory of CM relaxation, as Ca2+ 
would lead to a contraction of this muscle. However, the increase in US 
outflow is still considered the main mechanism of action for PGs analogs. 
Some studies proposed that PGF2α can promote a PG-induced PG release 
and that this may be an explanation for the mechanism of action of PGs 
analogs235. Moreover, although PGs have their respective receptor, 
natural PGs can bind with less affinity to the other PG receptors245. 
Therefore, the hypotensive effect of ghrelin related to prostaglandins 
release may be explained by an activation of receptors involved in the 
relaxation of the CM or the TM, decreasing resistance and increasing 
outflow. Although the effect related to prostaglandins’ analogs is highly 
related to a remodeling of the extracellular matrix by MMPs, it is unlikely 
that this effect could contribute to ghrelin’s decrease in IOP because 
ghrelin is responsible for an acute decrease in IOP. Nevertheless, 
because nothing is known about the effect of chronic administration of 
ghrelin in the IOP, the possibility of MMP formation cannot be discarded. 
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Conclusion 
The equilibrium between AqH production and drainage is responsible for 
a physiological IOP. When this equilibrium is disturbed either by an 
excessive production or an insufficient drainage the IOP rises. Ocular 
hypertension is the main cause for glaucoma which is one of the leading 
causes of blindness in the western world. The current therapy for 
glaucoma consists in surgical or pharmacological methods that focus in 
the reduction of IOP. The CM plays a pivotal role in the drainage 
mechanisms of the eye and most drugs that reduce the IOP have effects 
in this muscle.  
In our studies we have demonstrated ghrelin as potent hypotensive 
peptide. Indeed, this hypotensive effect was superior than that of 
current drugs used in the management of glaucoma. We have confirmed 
that ghrelin is locally produced in the ocular tissue. This production, 
along with the fact that this peptide‘s levels are reduced in glaucoma 
patients strongly suggests that this peptide may be involved in the 
pathophysiology of glaucoma.  
In addition to ghrelin, also GHSR is present in the ocular tissue, namely in 
the major components responsible for the regulation of aqueous 
humour. Considering ghrelin’s effect in IOP and the presence of its 
receptor in the ocular tissue, further studies should be performed to 
elucidate the mechanism responsible for ghrelin’s action.  
Taken together, these data suggest that the ghrelin and its receptor may 
play an important role in the ocular physiology. Also, they should be 
considered as potential therapeutic targets for glaucoma. 
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